1
|
Lejeune M, Menard B, Servais S, Andrianne C, Capelle L, De Maistre S, Fabaron C, Cornier MF, Goutagny MP, Pereira M, Tardy C, Turquet E, Benakli M, Baudoux E, Evard S, Faucher C, Herrero G, Magro L, Geurten C. [Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)]. Bull Cancer 2024:S0007-4551(24)00152-8. [PMID: 38755034 DOI: 10.1016/j.bulcan.2024.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2024] [Revised: 03/19/2024] [Accepted: 04/02/2024] [Indexed: 05/18/2024]
Abstract
Haematopoietic stem cell collection from paediatric donors is a common and life-saving practice, as evidenced by the fact that there is a growing annual number of cases of transplants from minor donors among SFGM-TC centers over the last decade. Still, medical use of human tissue from a healthy and underage donor requires proper regulations and medical management. The guidelines below aim at underlining the importance of pondering the legal, medical and ethical aspects of using stem cells from healthy paediatric donors and stress out the importance of obtaining informed consent at the time of assessing HLA compatibility. Combined medical and psychological assessments are required before the donation, as well as one month later and one year later to ensure of the child's physical and mental wellbeing. Bone marrow harvest under general anaesthetics remains the preferred method of collection for children. Peripheral blood stem cell collection should only be considered for children who will not require a central venous access for collection. We aim at offering guidelines centered on the healthy child donating stem cells and his/her wellbeing, and these should be regularly reviewed as medical practices evolve.
Collapse
Affiliation(s)
- Marie Lejeune
- Service d'hématologie, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Bertille Menard
- Service d'hématologie pédiatrique, hôpital de la Timone Enfants, AP-HM, 264, rue Saint-Pierre, 13005 Marseille, France
| | - Sophie Servais
- Service d'hématologie, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Christelle Andrianne
- Service d'hématologie, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Lucie Capelle
- Service d'hématologie pédiatrique, CHU de Lille, avenue Eugène-Avinée, 59000 Lille, France
| | - Ségolène De Maistre
- Service d'hématologie pédiatrique, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France
| | - Catherine Fabaron
- Service d'onco-hematologie pédiatrique, CHU Purpan Toulouse, 1, place du Dr Baylac, 31300 Toulouse, France
| | - Marie Flata Cornier
- Service d'hémato-oncologie pédiatrique, hôpitaux universitaires de Genève, rue Willy-Donzé, 1203 Genève, Suisse
| | - Marie-Pierre Goutagny
- Service d'hématologie pédiatrique, IHOPe, 1, place Joseph-Renaut, 69008 Lyon, France
| | - Maguy Pereira
- Service d'hématologie, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Clea Tardy
- Service de pharmacie, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France
| | - Eric Turquet
- Service d'onco-hematologie pédiatrique, CHU de Rennes, Hôpital Sud, 16, boulevard de Bulgarie, 35200 Rennes, France
| | - Malek Benakli
- Coordinateur national du groupe algérien de travail sur la Greffe de cellules souches hématopoïétiques (GATGCSH), Centre Pierre et Marie Curie, rue Tebessi Larbi, Sidi M'Hamed, 16000 Alger, Algérie
| | - Etienne Baudoux
- Laboratoire de thérapie cellulaire et génique, centre hospitalier universitaire de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Solène Evard
- Centre hospitalier universitaire de Rennes-Inserm, CIC-1414, centre d'investigation clinique de Rennes, 2, rue Henri-le-Guilloux, 35033 Rennes, France
| | - Catherine Faucher
- Agence de la biomédecine, 1, avenue du stade de France, 93212 Saint-Denis La Plaine cedex, France
| | - Gwenaelle Herrero
- Association de patients, rue de la Fontenette 23, 1227 Carouge,, Suisse
| | - Léonardo Magro
- LIRIC, Inserm U995, CHU de Lille, université de Lille, 59000 Lille, France
| | - Claire Geurten
- Service de pédiatrie, département d'hématologie pédiatrique, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique.
| |
Collapse
|
2
|
Ducassou S, Abou Chahla W, Duployez N, Halfon-Domenech C, Brethon B, Poirée M, Adam de Beaumais T, Lemaître L, Sirvent N, Petit A. [SFCE harmonization workshops: Neonatal acute myeloid leukemia]. Bull Cancer 2024; 111:513-524. [PMID: 38503585 DOI: 10.1016/j.bulcan.2023.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 11/28/2023] [Accepted: 12/07/2023] [Indexed: 03/21/2024]
Abstract
Neonatal acute myeloid leukemias (AML) occurred within the first 28 days of life and constitute only a small proportion of all AL. They are distinguished from leukemias of older children by their clinical presentation, which frequently includes cutaneous localizations ("blueberry muffin rash syndrome") and a leukocytosis above 50 ×109/L. This proliferation may be transient, causing a transient leukemoid reaction in a background of constitutional trisomy 21 ("Transient Abnormal Myelopoieseis" or TAM) or Infantile Myeloproliferative Disease in the absence of constitutional trisomy 21 ("Infantile Myeloproliferative Disease" or IMD). In cases of true neonatal AML, the prognosis of patients is poor. Overall survival is around 35 % in the largest historical series. This poor prognosis is mainly due to the period of onset of this pathology making the use of chemotherapy more limited and involving many considerations, both ethical and therapeutic. The objective of this work is to review this rare pathology by addressing the clinical, biological, therapeutic and ethical particularities of patients with true neonatal AML or transient leukemoid reactions occurring in a constitutional trisomy 21 (true TAM) or somatic background (IMD).
Collapse
Affiliation(s)
- Stéphane Ducassou
- Service d'hématologie et d'oncologie pédiatrique, CHU de Bordeaux, Bordeaux, France
| | | | | | - Carine Halfon-Domenech
- Service d'hématologie pédiatrique, institut d'hématologie et d'oncologie pédiatrique, hospices civils de Lyon, université Lyon 1, Lyon, France
| | - Benoît Brethon
- Service d'hématologie pédiatrique, hôpital Robert-Debré, AP-HP, Paris, France
| | - Marilyne Poirée
- Service d'hématologie et d'oncologie pédiatrique, CHU de Nice, Nice, France
| | | | - Laurent Lemaître
- Service d'hématologie et oncologie pédiatrique, CHU de Montpellier, Montpellier, France
| | - Nicolas Sirvent
- Service d'hématologie et oncologie pédiatrique, CHU de Montpellier, Montpellier, France
| | - Arnaud Petit
- Service d'hématologie et oncologie pédiatrique, hôpital Armand-Trousseau, AP-HP, Sorbonne université, Paris, France
| |
Collapse
|
3
|
Alsuliman T, Aubrun C, Bay JO, Beguin Y, Bigenwald C, Brissot E, Chalandon Y, Chevallier P, Pagliuca S, Magro L, Srour M. [Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024:S0007-4551(24)00119-X. [PMID: 38631984 DOI: 10.1016/j.bulcan.2024.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 02/12/2024] [Accepted: 02/19/2024] [Indexed: 04/19/2024]
Abstract
Chimeric antigen receptor T cell (CAR-T cell) therapy has become a standard-of-care for several hematological and a promising treatment for solid malignancies or for selected non-malignant autoimmune disorders. Hematological complications following this treatment are very common with the majority of patients experiencing at least one cytopenia after CAR-T cell injections. The management of these adverse events is not standardized and represents an area of active research and unmet clinical needs. This harmonization workshop, gathering a group of experts who analyzed this topic, has been conceived for the optimization of the management of patients presenting with post-CAR-T cell hematological toxicities. Based on the data present in the literature, these practical recommendations were made to harmonize the practices of Francophone centers involved in the management of these patients.
Collapse
Affiliation(s)
- Tamim Alsuliman
- Service d'hématologie et de thérapie cellulaire, hôpital Saint-Antoine, AP-HP Sorbonne université, 184, Faubourg-Saint-Antoine, 75012 Paris, France.
| | - Clotilde Aubrun
- Coordination greffe-hémato, CHU Ambroise-Paré, 2, boulevard Kennedy, 7000 Mons, Belgique.
| | - Jacques Olivier Bay
- Service de thérapie cellulaire et d'hématologie clinique adulte, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
| | - Yves Beguin
- Department of Hematology and GIGA Laboratory of Hematology, University Hospital of Liège and ULiège, Liège, Belgique.
| | - Camille Bigenwald
- Département d'hématologie, Gustave-Roussy, université Paris Saclay, Villejuif, France.
| | - Eolia Brissot
- Service d'hématologie et de thérapie cellulaire, hôpital Saint-Antoine, AP-HP Sorbonne université, 184, Faubourg-Saint-Antoine, 75012 Paris, France.
| | - Yves Chalandon
- Service d'hématologie, département d'oncologie, hôpitaux universitaire Genève (HUG) et faculté de médecine, université de Genève, Genève, Suisse.
| | | | - Simona Pagliuca
- Service d'hématologie, UMR 7365, IMoPA, CNRS, campus Brabois Santé, hôpitaux de Brabois, CHRU de Nancy, université de Lorraine, Vandœuvre-lès-Nancy, France.
| | - Léonardo Magro
- Maladies du sang, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France.
| | - Micha Srour
- Maladies du sang, hôpital Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France.
| |
Collapse
|
4
|
Strullu M, Cousin E, de Montgolfier S, Fenwarth L, Gachard N, Arnoux I, Duployez N, Girard S, Guilmatre A, Lafage M, Loosveld M, Petit A, Perrin L, Vial Y, Saultier P. [Suspicion of constitutional abnormality at diagnosis of childhood leukemia: Update of the leukemia committee of the French Society of Childhood Cancers]. Bull Cancer 2024; 111:291-309. [PMID: 38267311 DOI: 10.1016/j.bulcan.2023.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 11/06/2023] [Accepted: 11/17/2023] [Indexed: 01/26/2024]
Abstract
The spectrum of childhood leukemia predisposition syndromes has grown significantly over last decades. These predisposition syndromes mainly involve CEBPA, ETV6, GATA2, IKZF1, PAX5, RUNX1, SAMD9/SAMD9L, TP53, RAS-MAPK pathway, DNA mismatch repair system genes, genes associated with Fanconi anemia, and trisomy 21. The clinico-biological features leading to the suspicion of a leukemia predisposition are highly heterogeneous and require varied exploration strategies. The study of the initial characteristics of childhood leukemias includes high-throughput sequencing techniques, which have increased the frequency of situations where a leukemia predisposing syndrome is suspected. Identification of a leukemia predisposition syndrome can have a major impact on the choice of chemotherapy, the indication for hematopoietic stem cell transplantation, and screening for associated malformations and pathologies. The diagnosis of a predisposition syndrome can also lead to the exploration of family members and genetic counseling. Diagnosis and management should be based on dedicated and multidisciplinary care networks.
Collapse
Affiliation(s)
- Marion Strullu
- Hématologie et immunologie pédiatrique, hôpital Robert-Debré, GHU AP-HP Nord-Université Paris Cité, Paris, France; Inserm UMR_S1131, Institut universitaire d'hématologie, université Paris Cité, Paris cité, Paris, France.
| | - Elie Cousin
- Service d'onco-hématologie pédiatrique, CHU de Rennes, Rennes, France
| | - Sandrine de Montgolfier
- Aix Marseille université, Inserm, IRD, SESSTIM, sciences économiques & sociales de la santé & traitement de l'information médicale, ISSPAM, Marseille, France
| | - Laurene Fenwarth
- Département de génétique clinique, laboratoire d'hématologie, unité de génétique moléculaire des hémopathies malignes, CHU de Lille, université de Lille, Lille, France
| | | | | | - Nicolas Duployez
- Laboratoire d'hématologie, unité de génétique moléculaire des hémopathies malignes, CHU de Lille, université de Lille, Lille, France
| | - Sandrine Girard
- Service d'hématologie biologique, centre de biologie et pathologie Est, LBMMS, hospices civils de Lyon, Lyon, France
| | - Audrey Guilmatre
- Service d'hématologie et oncologie pédiatrique, hôpital Armand-Trousseau, AP-HP.Sorbonne Université, Paris, France
| | - Marina Lafage
- CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille université U105, laboratoire d'hématologie, CHU Timone, Marseille, France
| | - Marie Loosveld
- CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille université U105, laboratoire d'hématologie, CHU Timone, Marseille, France
| | - Arnaud Petit
- Service d'hématologie et oncologie pédiatrique, hôpital Armand-Trousseau, AP-HP.Sorbonne Université, Paris, France
| | - Laurence Perrin
- Génétique clinique, hôpital Robert-Debré, GHU AP-HP Nord-Université Paris cité, Paris, France
| | - Yoan Vial
- Inserm UMR_S1131, Institut universitaire d'hématologie, université Paris Cité, Paris cité, Paris, France; Laboratoire de génétique moléculaire, hôpital Robert-Debré, GHU AP-HP Nord-Université Paris cité, Paris, France
| | - Paul Saultier
- Service d'hématologie immunologie oncologie pédiatrique, Inserm, INRAe, C2VN, hôpital d'Enfants de la Timone, Aix Marseille université, AP-HM, Marseille, France
| |
Collapse
|
5
|
Yafour N, Couturier MA, Borel C, Charbonnier A, Coman T, Fayard A, Masouridi-Levrat S, Yakoub-Agha I, Roy J. [Second allogeneic (update). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S29-S39. [PMID: 37045732 DOI: 10.1016/j.bulcan.2023.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 03/05/2023] [Accepted: 03/08/2023] [Indexed: 04/14/2023]
Abstract
Relapse after allogeneic hematopoietic cell transplantation (allo-HCT) remains a major concern because it is associated with poor survival. A second allo-HCT is a valid option in this situation. During the 13th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to update the second allo-HCT recommendations elaborated during the previous workshop (2016). The main indication for a second allo-HCT remains relapse of initial hematologic malignancy. Disease status; complete remission (CR), and relapse time after the first allo-HCT>6 months impact positively the overall survival of patients after the second allo-HCT. Donor change is a valid option, particularly if there is HLA loss on leukemic cells after a first haploidentical or following a mismatched allo-HCT is documented. Reduced intensity conditioning is recommended, while a sequential protocol is a reasonable option in patients with proliferative disease. A post-transplant maintenance strategy after hematological recovery is recommended as soon as day 60, even if the immunosuppressive treatment has not yet been stopped. Hypomethylating agents, and targeted therapies such as anti FLT3, anti BCL2, anti-IDH1/2, TKI, anti-TP53, anti-CD33, anti-CD19, anti-CD22, anti-CD30, check point inhibitors, and CAR-T cells can be used as a bridge to transplant or as an alternative treatment to the second allo-HCT.
Collapse
Affiliation(s)
- Nabil Yafour
- Établissement hospitalier et universitaire 1(er) Novembre 1954, faculté de médecine, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn Rochd, université d'Oran 1, Ahmed-Ben-Bella, 31000 Oran, Algérie.
| | - Marie-Anne Couturier
- Hôpital Morvan, institut cancérologie-hématologie, CHRU Brest, 2, avenue Foch, 29200 Brest, France
| | - Cécile Borel
- CHU de Toulouse, institut universitaire du cancer de Toulouse Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France
| | - Amandine Charbonnier
- CHU d'Amiens, groupe hospitalier Amiens Sud, hématologie clinique et thérapie cellulaire, 80034 Amiens cedex 1, France
| | - Tereza Coman
- Institut Gustave-Roussy, département d'hématologie, 114, rue Edouard-Vaillant, Villejuif, France
| | - Amandine Fayard
- CHU de Clermont-Ferrand, service hématologie, 1, rue Lucie- et Raymond-Aubrac, 63003 Clermont-Ferrand, France
| | - Stavroula Masouridi-Levrat
- Hôpitaux universitaires de Genève, service d'hématologie, département d'oncologie, 4, rue Gabrielle-Perret-Gentil, 1205 Genève, Suisse
| | - Ibrahim Yakoub-Agha
- Inserm U1286, Infinite, CHU de Lille, université de Lille, 59000 Lille, France
| | - Jean Roy
- Hôpital maisonneuve-rosemont, université de Montréal, Montréal, Québec, Canada
| |
Collapse
|
6
|
Xhaard A, Bouton M, Delugin L, Giraud C, Guyon A, Giroux-Lathuile C, Hajjout K, Nicolas P, Peyrard T, Ratie V, Boisnard A, Capelle L, Godin S, Traineau R, Yacoub-Agha I, Leprêtre AC. [Transfusion management and immuno-hematological follow-up after allogeneic hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S78-S83. [PMID: 37055307 DOI: 10.1016/j.bulcan.2023.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 03/07/2023] [Accepted: 03/08/2023] [Indexed: 04/15/2023]
Abstract
The French High Authority of Health (HAS) and National Drug Safety (ANSM) agencies recommendations issued in 2014, the French General Direction of Health (DGS) instruction published in November 2021, the French National Blood Bank (EFS) guidelines and the data available in the literature globally define "good transfusion practices" but provide little information about the immuno-hematological and transfusion management of patients who have received an allogeneic hematopoietic stem transplantation (allo-HCT). The aim of this workshop was to harmonize these practices in situations for which there are currently no recommendations. In order to anticipate possible transfusion issues after allo-HCT, we recommend performing, before the transplantation, an extended red blood cell phenotyping of the donor and a detection of HLA alloimmunization in the recipient. We recommend to systematically perform for minor ABO mismatches: a direct antiglobulin test between D8 and D20, and for major ABO mismatches; a titration of anti-A/anti-B antibodies and an erythrocyte chimerism at D100. At one-year post-transplant, we recommend carrying out an erythrocyte chimerism to allow, if necessary, the update of transfusion counselling (RH phenotype, irradiation of packed red blood cells).
Collapse
Affiliation(s)
- Aliénor Xhaard
- AP-HP, hôpital Saint-Louis, service d'hématologie-greffe, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - Muriel Bouton
- EFS Nouvelle-Aquitaine, site de Pessac Haut-Lévêque, avenue de Magellan, Pessac, France
| | - Laurence Delugin
- EFS Bretagne, laboratoire immuno-hématologie érythrocytaire, rue Pierre-Jean-Gineste, 35011 Rennes cedex, France
| | - Christine Giraud
- CHU de Poitiers, service d'hématologie et de thérapie cellulaire, 2, rue de la Miletrie, 86021 Poitiers, France; Centre de soins, EFS NVAQ, site de Poitiers, laboratoire de thérapie cellulaire, 350, avenue Jacques-Cœur, BP 482, 86012 Poitiers cedex, France
| | - Alizée Guyon
- EFS Bourgogne-Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France
| | | | - Khadija Hajjout
- Centre régional de transfusion sanguine de Rabat, Rabat, Maroc
| | - Pascal Nicolas
- EFS Grand-Est, 10, rue Spielmann, 67000 Strasbourg, France
| | | | - Vanessa Ratie
- EFS Bourgogne-Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France
| | - Anne Boisnard
- AP-HP, hôpital Necker, service d'hématologie adulte, 151, rue de Sèvres, 75015 Paris, France
| | - Lucie Capelle
- CHU de Lille, service hématologie pédiatrique, Lille, France
| | - Sandrine Godin
- CHU de Lille, service hématologie pédiatrique, Lille, France
| | | | - Ibrahim Yacoub-Agha
- Université de Lille, CHU de Lille, Infinite, Inserm U1286, 59000 Lille, France
| | | |
Collapse
|
7
|
Polomeni A, Ainaoui M, Berr A, de Bentzman N, Denis M, Friser V, Magro L, Yakoub-Agha I. [Allogeneic hematopoietic stem cell transplantation and treatment with CAR-T cells - identification of psycho-social vulnerability factors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S67-S77. [PMID: 37169605 DOI: 10.1016/j.bulcan.2023.03.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Revised: 03/29/2023] [Accepted: 03/31/2023] [Indexed: 05/13/2023]
Abstract
Allogeneic hematopoietic stem cell transplantation (HCT) and CAR-T cells therapy are treatments with curative aim for certain hematological malignancies, refractory or relapse. Nevertheless, they carry the risk of morbidity and mortality and may have a significant psychosocial impact, particularly for HCT. It is therefore necessary to identify psychological difficulties and social problems, as well as the patient's resources, and those of his entourage, in order to improve his overall management. The objective of this evaluation is not to pose contraindications to treatments, but to adapt the personalized care project. This identification must be carried out early on in the pre-HCT assessment journey to enable the implementation of appropriate actions by the various care providers. Based on a review of the literature, we designed a psychosocial data collection grid that can be initiated in pre-transplant and updated by accompanying the patient at each stage of follow-up (discharge from hospital, day-hospital follow-up, D100 evaluation). This grid is divided into 3 axes: socio-family context, psychological and somatic aspects. This tool allows the traceability of the interventions of different professionals and is a support for multidisciplinary exchanges.
Collapse
Affiliation(s)
- Alice Polomeni
- Assistance publique-Hôpitaux de Paris, hôpital St-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du faubourg St-Antoine, 75012 Paris, France.
| | - Malika Ainaoui
- CHU de Lille, service des maladies du sang, rue Michel-Polonoski, 59037 Lille cedex, France
| | - Aurélie Berr
- Institut de cancérologie Strasbourg Europe, service des soins de support, 17, rue Albert-Calmette BP 23025, 67033 Strasbourg cedex, France
| | - Natacha de Bentzman
- IUCT Oncopole 1, service hématologie-greffe, avenue Irène-Joliot-Curie, 31059 Toulouse, France
| | - Marie Denis
- Pôle régional de cancérologie, rue de la Milétrie, 86000 Poitiers, France
| | - Valérie Friser
- Assistance publique-Hôpitaux de Paris, hôpital Pitié-Salpétrière, service d'hématologie clinique, 43-83, boulevard de l'hôpital Pavillon Georges-Heuyer, 75013 Paris, France
| | - Leonardo Magro
- CHU de Lille, service des maladies du sang, rue Michel Polonoski, 59037 Lille cedex, France
| | | |
Collapse
|
8
|
Cornillon J, Crocchiolo R, Dubois V, Guidicelli G, Jorge-Cordeiro D, Meunier MC, Michiels S, Timmermans A, Villemonteix J, Yakoub-Agha I, Ahmad I. [Unrelated donor selection for allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S1-S13. [PMID: 37690877 DOI: 10.1016/j.bulcan.2023.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 07/18/2023] [Accepted: 07/19/2023] [Indexed: 09/12/2023]
Abstract
The selection of a donor is an essential element in allogeneic hematopoietic stem cell transplantation. In the absence of an HLA-matched related donor, the selection of an unrelated donor is considered, and is currently the most common type of allogenic donor used in practice. Many criteria are considered for the selection when multiple donors are available, particularly in case of partial match. The aim of this workshop is to assist in the selection of an unrelated donor, in keeping with recent data from the literature.
Collapse
Affiliation(s)
- Jérôme Cornillon
- Centre hospitalo-universitaire de Saint-Étienne 42, département d'hématologie et de thérapie cellulaire, Saint-Étienne, France.
| | | | | | | | - Debora Jorge-Cordeiro
- Université Paris-Cité, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Louis, laboratoire d'immunologie, Paris, France
| | - Marie-Christine Meunier
- Hôpital Maisonneuve-Rosemont, Optilab-CHUM, laboratoire de diagnostic moléculaire et cytogénétique, Montréal, Québec, Canada
| | - Sandra Michiels
- Hôpital universitaire de Bruxelles, institut Jules-Bordet, unité de transplantation-hématologie, Bruxelles, Belgique
| | - Aurélie Timmermans
- Hôpital universitaire de Bruxelles, institut Jules-Bordet, unité de transplantation-hématologie, Bruxelles, Belgique
| | - Juliette Villemonteix
- Université Paris-Cité, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Louis, laboratoire d'immunologie, Paris, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, Inserm U1286, Infinite, université de Lille, 59000 Lille, France
| | - Imran Ahmad
- Université de Montréal, hôpital Maisonneuve-Rosemont, institut universitaire d'hématologie-oncologie & de thérapie cellulaire, Montréal, Québec, Canada
| |
Collapse
|
9
|
Amokrane K, Cherel M, Rouzaire PO, Walencik A, Dubois V. [Relapse with HLA loss after hematopoietic stem cell transplantation with non-HLA identical donor: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer 2024; 111:S14-S21. [PMID: 37061368 DOI: 10.1016/j.bulcan.2023.03.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 03/13/2023] [Accepted: 03/15/2023] [Indexed: 04/17/2023]
Abstract
Loss of heterozygosity or HLA loss is a genomic-type escape mechanism highlighted in certain types of relapses after allogeneic hematopoietic stem cell transplantation with a non-HLA identical donor, and especially after haplo-identical transplantation. The diagnosis must be made with certainty because the result conditions the therapy. In this article, the different mechanisms and techniques that can be used for the diagnosis of loss of heterozygosity, as well as the therapeutic options are reviewed, making it possible to establish clinico-biological recommendations for the diagnosis confirmation and management of the patients in relapse.
Collapse
Affiliation(s)
- Kahina Amokrane
- Gustave-Roussy, centre de lutte contre le cancer, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| | | | - Paul-Olivier Rouzaire
- EA(UR)7453 CHELTER-université de Clermont Auvergne, service d'histocompatibilité et d'immunogénétique, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Alexandre Walencik
- EFS Centre-Pays de la Loire, laboratoire histocompatibilité, Nantes, France
| | - Valérie Dubois
- Laboratoire HLA, EFS Auvergne Rhône Alpes, Lyon, France.
| |
Collapse
|
10
|
Bonnin A, Terriou L, Beuvon C, Tudesq JJ, Puyade M, Pugnet G, Maria A, Llorente CC, Lansiaux P, Cacciatore C, Badoglio M, Yakoub-Agha I, Farge-Bancel D, Marjanovic Z. [Mobilization and conditioning protocols actualization for autologous stem cell transplantation for autoimmune diseases: Guidelines from MATHEC-SFGM-TC]. Bull Cancer 2024; 111:S84-S95. [PMID: 37845095 DOI: 10.1016/j.bulcan.2023.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 08/25/2023] [Accepted: 09/01/2023] [Indexed: 10/18/2023]
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 13th workshop on hematopoietic stem cell transplantation clinical practices harmonization procedures in September 2022 in Lille, France. The aim of this workshop is to update the mobilization and conditioning protocols for autologous hematopoietic stem cell transplantation for autoimmune diseases, and to specify contraindications for transplant, conditioning regimen selection, immunosuppressive treatment discontinuation before mobilization and disease-specific surveillance.
Collapse
Affiliation(s)
- Agnès Bonnin
- AP-HP, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - Louis Terriou
- CHU de Lille, département de médecine interne et immunologie clinique, 59000 Lille, France; Centre de référence des maladies auto-immunes et auto-inflammatoires rares (CERAINO), 59000 Lille, France
| | - Clément Beuvon
- CHU de Poitiers, service de médecine interne, 2, rue de La Miletrie, 86021 Poitiers, France
| | - Jean-Jacques Tudesq
- Université de Montpellier, CHU de Montpellier, service d'hématologie clinique, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - Mathieu Puyade
- CHU de Poitiers, service de médecine interne, 2, rue de La Miletrie, 86021 Poitiers, France
| | - Grégory Pugnet
- CHU de Toulouse Rangueil, service de médecine interne et immunologie clinique, 2, rue Viguerie, 31059 Toulouse, France
| | - Alexandre Maria
- CHU de Montpellier, hôpital Saint-Eloi, Université de Montpellier, Institute for Regenerative Medicine and Biotherapy (IRMB), médecine interne et immuno-oncologie (MedI20), 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - Cristina Castilla Llorente
- Gustave-Roussy Cancer Campus, département d'hématologie, 114, rue Edouard-Vaillant, 94805 Villejuif, France
| | - Pauline Lansiaux
- AP-HP, hôpital St-Louis, centre de référence des maladies auto-immunes systémiques rares d'Île-de-France MATHEC (FAI2R), unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF 04), 1, avenue Claude-Vellefaux, 75010 Paris, France; Université de Paris Cité, institut de recherche Saint-Louis, recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France
| | - Carlotta Cacciatore
- AP-HP, hôpital St-Louis, centre de référence des maladies auto-immunes systémiques rares d'Île-de-France MATHEC (FAI2R), unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF 04), 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - Manuela Badoglio
- Hôpital Saint-Antoine, EBMT Office, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France
| | | | - Dominique Farge-Bancel
- AP-HP, hôpital St-Louis, centre de référence des maladies auto-immunes systémiques rares d'Île-de-France MATHEC (FAI2R), unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF 04), 1, avenue Claude-Vellefaux, 75010 Paris, France; Université de Paris Cité, institut de recherche Saint-Louis, recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France; McGill University, H3A 1A1, Department of Medicine, Montreal, Canada
| | - Zora Marjanovic
- AP-HP, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France.
| |
Collapse
|
11
|
Conrad A, Beguin Y, Guenounou S, Le Bourgeois A, Ménard AL, Rialland F, Layal S, Mamez AC, Yakoub-Agha I, El Cheikh J. [Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S40-S49. [PMID: 37479644 DOI: 10.1016/j.bulcan.2023.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Revised: 05/06/2023] [Accepted: 05/12/2023] [Indexed: 07/23/2023]
Abstract
During immune reconstitution following allogeneic haematopoietic stem cell transplantation (allo-HSCT), (re)vaccination of allo-HSCT recipients is recommended. Herein, we propose an update of practical recommendations regarding vaccination of allo-HSCT recipients. These recommendations, based on data from the literature, national and international guidelines and the consensus of the participants when no formally proven data are available, were elaborated during the workshop of practice harmonization organized by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in Lille in September 2022.
Collapse
Affiliation(s)
- Anne Conrad
- Hospices civils de Lyon, hôpital de la Croix-Rousse, service des maladies infectieuses et tropicales, 103, grande rue de la Croix-Rousse, 69004 Lyon, France.
| | - Yves Beguin
- CHU de Liège, université de Liège, service d'hématologie, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Sarah Guenounou
- CHU de Toulouse, Institut universitaire du cancer de Toulouse, oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France
| | - Amandine Le Bourgeois
- CHU de Nantes, service d'hématologie, 1, place Alexis-Ricordeau, 44000 Nantes, France
| | - Anne-Lise Ménard
- Centre Henri-Becquerel, département d'hématologie clinique, rue d'Amiens, 76038 Rouen, France
| | - Fanny Rialland
- CHU de Nantes, HME, 7, quai Moncousu, 44000 Nantes, France
| | - Sharrouf Layal
- American University of Beirut Medical Center (AUBMC), division oncologie-hématologie, département de médecine interne, Beyrouth, Liban
| | - Anne-Claire Mamez
- University of Geneva, Geneva University Hospitals, Department of Oncology, Division of Hematology, Geneva, Suisse
| | | | - Jean El Cheikh
- American University of Beirut Medical Center (AUBMC), division oncology-hematology BMT program, département de médecine interne, Beyrouth, Liban
| |
Collapse
|
12
|
Loschi M, Alsuliman T, Cabrera Q, Desbrosses Y, Desmier D, Yakoub Agha I, Guillaume T. [Secondary cancers following allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S22-S28. [PMID: 36922321 DOI: 10.1016/j.bulcan.2023.02.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 02/10/2023] [Accepted: 02/26/2023] [Indexed: 03/15/2023]
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held the 13th edition of the Clinical Practices Harmonization Workshops. Our workgroup reviewed the current data on the incidence, screening methods and international guidelines for the prevention of secondary solid cancers following allogeneic hematopoietic stem cell transplantation. The purpose of this workshop was to provide recommendations for the screening and prevention of secondary malignancies to Francophone transplantation centers.
Collapse
Affiliation(s)
- Michael Loschi
- CHU de Nice, université Cote d'Azur, Inserm 1065, service d'hématologie clinique et thérapie cellulaire, 06000 Nice, France.
| | - Tamim Alsuliman
- AP-HP, Sorbonne université, hôpital Saint-Antoine, service d'hématologie, 75012 Paris, France
| | - Quentin Cabrera
- CHU Réunion Sud, service d'hématologie clinique, site de Saint-Pierre, Saint-Pierre, Réunion
| | | | - Deborah Desmier
- CHU de Poitiers, onco-hématologie clinique et thérapie cellulaire, 86000 Poitiers, France
| | | | - Thierry Guillaume
- CHU de Nantes, Hôtel-Dieu, service d'hématologie clinique, 44000 Nantes, France
| |
Collapse
|
13
|
Yakoub-Agha I, Greco R, Onida F, de la Cámara R, Ciceri F, Corbacioglu S, Dolstra H, Glass B, Kenyon M, McLornan DP, Neven B, de Latour RP, Peric Z, Ruggeri A, Snowden JA, Sureda A, Sánchez-Ortega I. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplant 2023:10.1038/s41409-023-01958-w. [PMID: 36973515 DOI: 10.1038/s41409-023-01958-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 02/21/2023] [Accepted: 03/13/2023] [Indexed: 03/29/2023]
Abstract
AbstractFor hematopoietic cell transplantation (HCT) and cellular therapy (CT), clinical patient care is localized, and practices may differ between countries and from center to center even within the same country. Historically, international guidelines were not always adapted to the changing daily clinical practice and practical topics there were not always addressed. In the absence of well-established guidelines, centers tended to develop local procedures/policies, frequently with limited communication with other centers. To try to harmonize localized clinical practices for malignant and non-malignant hematological disorders within EBMT scope, the practice harmonization and guidelines (PH&G) committee of the EBMT will co-ordinate workshops with topic-specific experts from interested centers. Each workshop will discuss a specific issue and write guidelines/recommendations that practically addresses the topic under review. To provide clear, practical and user-friendly guidelines when international consensus is lacking, the EBMT PH&G committee plans to develop European guidelines by HCT and CT physicians for peers’ use. Here, we define how workshops will be conducted and guidelines/recommendations produced, approved and published. Ultimately, there is an aspiration for some topics, where there is sufficient evidence base to be considered for systematic reviews, which are a more robust and future-proofed basis for guidelines/recommendations than consensus opinion.
Collapse
|
14
|
[Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC]. Bull Cancer 2023; 110:S123-S131. [PMID: 35094839 DOI: 10.1016/j.bulcan.2021.12.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 12/08/2021] [Accepted: 12/12/2021] [Indexed: 11/20/2022]
Abstract
The immune effector cell-associated syndrome (ICANS) has been described as the second most frequent specific complication following CAR-T cell therapy. The median time to the onset of neurological symptoms is five days after CAR-T infusion. ICANS can be concomitant to cytokine release syndrome but often follows the resolution of the latter. However, 10 % of patients experience delayed onset after 3 weeks of CAR-T cell infusion. The duration of symptoms is usually short, around five days if an early appropriate treatment is given. Symptoms are heterogeneous, ranging from mild symptoms quickly reversible (alterations of consciousness, deterioration in handwriting) to more serious forms with seizures or even a coma. The ICANS severity is currently based on the ASTCT score. The diagnosis of ICANS is clinical but EEG, MRI and lumbar punction can help ruling out alternative diagnoses. The first line treatment consists of high-dose corticosteroids. During the twelfth edition of practice harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a working group focused its work on updating the SFGM-TC recommendations on the management of ICANS. In this review we discuss the management of ICANS and other neurological toxicities in patients undergoing of CAR-T cell therapy. These recommendations apply to commercial CAR-T cells, in order to guide strategies for the management neurological complications associated with this new therapeutic approach.
Collapse
|
15
|
Coiteux V, Fenwarth L, Duployez N, Ainaoui M, Borel C, Polomeni A, Yakoub-Agha I, Chalandon Y. [Management of genetic predisposition to hematologic malignancies in patients undergoing allogeneic hematopoietic cell transplantation (HCT): Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S13-S29. [PMID: 36307324 DOI: 10.1016/j.bulcan.2022.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 09/04/2022] [Accepted: 09/05/2022] [Indexed: 11/06/2022]
Abstract
The advent of new technologies has made it possible to identify genetic predispositions to myelodysplastic syndromes (MDS) and acute leukemias (AL) more frequently. The most frequent and best characterized at present are mutations in CEBPA, RUNX1, GATA2, ETV6 and DDX41 and, either in the presence of one of these mutations with a high allelic frequency, or in the case of a personal or family history suggestive of blood abnormalities such as non-immune thrombocytopenia, it is recommended to look for the possibility of a hereditary hematological malignancy (HHM). Indeed, early recognition of these HHMs allows better adaptation of the management of patients and their relatives, as allogeneic hematopoietic stem cell transplantation (HSCT) is very often proposed for these pathologies. According to current data, with the exception of the GATA2 mutation, the constitutional or somatic nature of the mutations does not seem to influence the prognosis of hematological diseases. Therefore, the indication for an allograft will be determined according to the usual criteria. However, when searching for a family donor, it is important to ensure that there is no hereditary disease in the donor. In order to guarantee the possibility of performing the HSC allograft within a short period of time, it may be necessary to initiate a parallel procedure to find an unrelated donor. Given the limited information on the modalities of HSC transplantation in this setting, it is important to assess the benefit/risk of the disease and the procedure to decide on the type of conditioning (myeloablative or reduced intensity). In view of the limited experience with the risk of secondary cancers in the medium and long-term, it may be appropriate to recommend reduced intensity conditioning, as in the case of better characterized syndromic hematological diseases such as Fanconi anemia or telomere diseases. In summary, it seems important to evoke HHM more frequently, particularly in the presence of a family history, certain mutations or persistent blood abnormalities, in order to discuss the specific modalities of HSC allografting, particularly with regard to the search for a donor and the evaluation of certain modalities of the procedure, such as conditioning. It should be noted that the discovery of HHM, especially if the indication of an allogeneic HSC transplant is retained, will raise ethical and psychological considerations not only for the patient, but also for his family. A multidisciplinary approach involving molecular biologists, geneticists, hematologists and psychologists is essential.
Collapse
Affiliation(s)
- Valérie Coiteux
- Hôpital Huriez, CHU de Lille, service de maladies du sang, 1, place de Verdun, 59037 Lille cedex, France.
| | - Laurène Fenwarth
- Université de Lille, CHU de Lille, CNRS, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Inserm, 59000 Lille, France
| | - Nicolas Duployez
- Université de Lille, CHU de Lille, CNRS, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Inserm, 59000 Lille, France
| | - Malika Ainaoui
- Hôpital Huriez, hôpital Fontan, CHU de Lille, service de maladies du sang, service de psychiatrie de liaison, 1, place de Verdun, 59037 Lille cedex, France
| | - Cécile Borel
- CHU de Toulouse, institut universitaire du cancer de Toulouse Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France
| | - Alice Polomeni
- AP-HP, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du faubourg Saint-Antoine, 75012 Paris, France
| | | | - Yves Chalandon
- Université de Genève, hôpitaux universitaires de Genève, faculté de médecine, service d'hématologie, 4, rue Gabrielle-Perret-Gentil, 1211 Genève, Suisse.
| |
Collapse
|
16
|
Dequirez PL, Magro L, Alsuliman T, Ceballos P, Desbrosses Y, Yakoub-Agha I, Guillaume T. [Haemorrhagic cystitis following hematopoietic stem cell transplantation: Prophylaxis, diagnosis, and treatment. Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S48-S55. [PMID: 35181061 DOI: 10.1016/j.bulcan.2022.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 01/10/2022] [Accepted: 01/10/2022] [Indexed: 10/19/2022]
Abstract
Hemorrhagic cystitis (HC) is a common complication after allogeneic hematopoietic cell transplantation (allo-HCT). Its manifestations range from microscopic hematuria without urinary symptoms to extensive and prolonged macroscopic hemorrhage requiring invasive interventions that can often prolong the duration of hospitalization and result in significant morbidity. The early onset of HC is related to allo-HCT conditioning regimen, whereas the late onset form is secondary to viral infection, most commonly due to BK virus. In the framework of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) practice harmonization workshops held in Lille in September 2021, the prophylaxis, the diagnostic approach and the treatments of HC following allografting were reviewed after analysis of published studies.
Collapse
Affiliation(s)
- Pierre-Luc Dequirez
- CHU de Lille, service d'urologie, 2, rue Michel-Polonowski, 59000 Lille, France
| | - Leonardo Magro
- CHU de Lille, service des maladies du sang, 2, rue Michel-Polonowski, 59000 Lille, France
| | - Tamim Alsuliman
- AP-HP, Sorbonne université, service d'hématologie et de thérapie cellulaire, hôpital Saint-Antoine, 184, rue Faubourg St-Honoré, 75012 Paris, France
| | - Patrice Ceballos
- CHU Saint-Éloi, service d'hématologie clinique, 80, avenue Bertin-Sans, 34080 Montpellier cedex 8, France
| | - Yohan Desbrosses
- CHRU Jean-Minjoz, service d'hématologie, 3, boulevard Fleming, 25030 Besançon cedex, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, université de Lille, service d'hématologie, Infinite, Inserm U1286, 59000 Lille, France
| | - Thierry Guillaume
- CHU de Nantes, Hôtel-Dieu, service d'hématologie, 1, place Ricordeau, 44000 Nantes, France.
| |
Collapse
|
17
|
Maria ATJ, Campidelli A, Castilla-Llorente C, Lansiaux P, Marjanovic Z, Pugnet G, Torregrosa-Diaz JM, Terriou L, Algayres JP, Urbain F, Yakoub-Agha I, Farge D. [Vaccination before and after autologous hematopoietic cell transplantation for autoimmune diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (MATHEC-SFGM-TC)]. Bull Cancer 2023; 110:S97-S107. [PMID: 36658011 DOI: 10.1016/j.bulcan.2022.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 11/16/2022] [Accepted: 11/16/2022] [Indexed: 01/18/2023]
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 12th workshop on hematopoietic stem cell transplantation clinical practices harmonization procedures on September 2021 in Lille, France. In the absence of specific national or international recommendation, the French working group for autologous stem Cell transplantation in Auto-immune Diseases (MATHEC) proposed guidances for vaccinations of patients undergoing autologous hematopoietic stem cell transplantation for autoimmune disease, including in the context of SARS-Cov-2 pandemic.
Collapse
Affiliation(s)
- Alexandre Thibault Jacques Maria
- Médecine Interne & Immuno-Oncologie (MedI2O), Institute for Regenerative Medicine & Biotherapy (IRMB), Hôpital Saint Eloi, CHU de Montpellier, 80 avenue Augustin Fliche, Montpellier, France; IRMB, Inserm U1183, Hôpital Saint-Eloi, CHU de Montpellier, 34295, Montpellier, France
| | - Arnaud Campidelli
- CHRU Nancy, Service Hématologie Adulte, 54500 Vandoeuvre-lès-Nancy, France
| | - Cristina Castilla-Llorente
- Gustave Roussy Cancer Campus, Département d́Hématologie, 114 rue Edouard Vaillant, 94800 Villejuif, France
| | - Pauline Lansiaux
- Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), AP-HP, Hôpital St-Louis, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), 75010 Paris, France; Université de Paris Cité, Institut de recherche Saint Louis, Recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France
| | - Zora Marjanovic
- Hôpital Saint Antoine (APHP), Service d'Hématologie et Thérapie cellulaire, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - Grégory Pugnet
- CHU Rangueil, Service de Médecine Interne et Immunologie Clinique, 1 avenue du Pr Jean Poulhès, 31059 Toulouse Cedex 9, France
| | | | - Louis Terriou
- Hôpital Claude Huriez, CHRU Lille, Service de médecine interne et immunologie clinique, rue Michel Polonovski, 59000 Lille, France
| | - Jean-Pierre Algayres
- Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), AP-HP, Hôpital St-Louis, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), 75010 Paris, France
| | - Fanny Urbain
- Hôpital Bicêtre, Groupe Hospitalier Universitaire Paris Sud, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne et Immunologie Clinique, 94275 Le Kremlin-Bicêtre cedex, France; Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France
| | | | - Dominique Farge
- Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), AP-HP, Hôpital St-Louis, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), 75010 Paris, France; Université de Paris Cité, Institut de recherche Saint Louis, Recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France; McGill University, Department of Medicine, H3A 1A1, Montreal, Canada.
| |
Collapse
|
18
|
Souchet L, Masouridi S, Marçais A, Ibrahim A, Chauvel C, Turquet E, Derail M, Yakoub-Agha I, Crocchiolo R. [Diagnosis, prophylaxis and therapeutic management of acute GVH: Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S79-S87. [PMID: 36437127 DOI: 10.1016/j.bulcan.2022.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 11/02/2022] [Accepted: 11/02/2022] [Indexed: 11/25/2022]
Abstract
Acute GVHD is a potentially severe complication of hematopoietic stem cell transplantation, responsible for morbidity and mortality that can affect the prognosis after transplantation. Within the framework of the 12th workshop of practice harmonization of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), diagnostic modalities of acute GVHD are updated. The conventional prevention (depending on donor, conditioning, and stem cell source) and treatment schemes (depending on affected organ and intensity) of aGVHD are clarified, and new therapeutic options are discussed.
Collapse
Affiliation(s)
- Laetitia Souchet
- Hôpital Pitié Salpêtrière, Service d'hématologie clinique, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
| | - Stavroula Masouridi
- Hôpitaux universitaires de Genève, Service d'hématologie, 4, rue Gabrielle-Perret-Gentil, 1211 Genève, Suisse
| | - Ambroise Marçais
- Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Service Hématologie Adultes, Hôpital Necker Enfants Malades, Paris, France
| | | | | | - Eric Turquet
- CHU Rennes, Service d'hématologie, Rennes, France
| | | | | | - Roberto Crocchiolo
- Service d'Aphérèse Thérapeutique, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italie
| |
Collapse
|
19
|
Bruno B, Capelle L, Denis V, Duval O, Selmouni S, Villate A, Cabelguenne D, Coiteux V, Lachner-Gaubert T, Yakoub-Agha I, Simon N. [Drug-drug interactions and physicochemical incompatibilities during acute phase after allo-SCT: Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S88-S96. [PMID: 35523598 DOI: 10.1016/j.bulcan.2022.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 02/03/2022] [Accepted: 02/05/2022] [Indexed: 10/18/2022]
Abstract
Since patients require multiple intravenous drugs, drug incompatibilities and drug interactions are frequent during the acute phase following hematopoietic cell transplantation. The risk of drug-drug interactions is increased in patients with several comorbidities. The goal of this workshop was to learn how to mitigate the risks of drug incompatibilities and interactions when their usage is therapeutically warranted. Our focus was on proton pump inhibitors and antiemetic drugs as they are routinely used in hematopoietic transplants and frequently lead to incompatibilities and interactions with other drugs such as immunosuppressives and antimicrobials. Routine procedures in transplantation such as the choice of vascular access devices, the setting of infusion lines, the scheduling of administration of drugs and their dilution volumes can be effective armaments to mitigate the risks of drug incompatibilities and interactions. In addition, a multidisciplinary concertation between clinicians, pharmacists and nurses is a key point in the success of patient's care.
Collapse
Affiliation(s)
- Bénédicte Bruno
- CHU Lille, service d'hématologie pédiatrique, 59000 Lille, France
| | - Lucie Capelle
- CHU Lille, service d'hématologie pédiatrique, 59000 Lille, France
| | - Virginie Denis
- CHU Rouen, service d'hématologie pédiatrique, 76000 Rouen, France
| | - Olivier Duval
- CHU Angers, service des maladies du sang, 49000 Angers, France
| | - Sorea Selmouni
- CHU Lille, service d'hématologie pédiatrique, 59000 Lille, France
| | - Alban Villate
- CHU Tours, service d'hématologie, 37000 Tours, France
| | | | - Valérie Coiteux
- CHU de Lille, université de Lille, Infinite, Inserm U1286, 59000 Lille, France
| | | | - Ibrahim Yakoub-Agha
- CHU de Lille, université de Lille, Infinite, Inserm U1286, 59000 Lille, France
| | - Nicolas Simon
- Université Lille, CHU Lille, ULR 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), 59000 Lille, France.
| |
Collapse
|
20
|
Yafour N, Hamzy F, Elkababri M, Yakoub-Agha I, Bekadja MA. [Acute lymphoblastic leukemia in developing countries: Management from the transplant indication (allo/auto) until post-transplant follow-up. Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S30-S38. [PMID: 35562231 DOI: 10.1016/j.bulcan.2022.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Revised: 02/16/2022] [Accepted: 02/18/2022] [Indexed: 11/26/2022]
Abstract
Management of acute lymphoblastic leukemia (ALL) patients in countries with limited resources depends on the means of prognostic stratification, available treatment and logistics. During the 12th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines for allogeneic hematopoietic cell transplantation (Allo-HCT) in this disease. Conventional poor prognostic factors can be used to determine the indication of allo-HCT in first remission. Patients lacking a HLA-matched related donor can be allografted with a haploidentical donor allo-HCT if available. Chemotherapy based conditioning regimen can be used if TBI is not available, because the probability to find a radiotherapy department with the capacity for total body irradiation is low. For patients with Philadelphia chromosome positive (Phi+) ALL, post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended. Autologous HCT is optional for Phi+ ALL patients with negative minimal residual disease, who not eligible for allo-HCT. Patients with refractory/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells.
Collapse
Affiliation(s)
- Nabil Yafour
- Université d'Oran 1, Ahmed-Ben-Bella, établissement hospitalier et universitaire 1(er) Novembre 1954, faculté de médecine, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn-Rochd, 31000 Oran, Algérie.
| | - Faty Hamzy
- Hôpital Cheikh-Zaïd universitaire international, service d'hématologie et greffe, cité Al-Irfane-Hay Ryad avenue Allal-al-Fassi, 10000 Rabat, Maroc
| | - Maria Elkababri
- Hôpital d'enfants de Rabat, université Mohammed V de Rabat, service d'hématologie et oncologie pédiatrique, Rabat, Maroc
| | | | - Mohamed Amine Bekadja
- Université d'Oran 1, Ahmed-Ben-Bella, établissement hospitalier et universitaire 1(er) Novembre 1954, faculté de médecine, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn-Rochd, 31000 Oran, Algérie
| |
Collapse
|
21
|
Srour M, Fayard A, Giannotti F, Giltat A, Guenounou S, Roy J, Schmitt J, Servais S, Alsuliman T, Agha IY, Guillerm G. [Graft failure, poor graft function erythroblastopenia: Actualization of definitions, diagnosis and treatment: Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S67-S78. [PMID: 36307323 DOI: 10.1016/j.bulcan.2022.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 09/03/2022] [Accepted: 09/05/2022] [Indexed: 11/06/2022]
Abstract
In this article, we discuss again the definition, the risk factor and guideline to treat the graft failure, the poor graft function and erythrobalstopenia. Graft failure is a severe but rare complication after hematopoietic cell transplantation (HCT). Despite disparity in the literature, we defined this complication and discussed the factor risks and recommendation for treatment based on new studies. Poor graft function is also a more frequent complication after HCT. New studies will soon be available to prove or not the current recommendation suggested in this article based on therapeutics medicine or cellular therapy. Erythroblastopenia, is a rarer complication post HCT. Despite anticipation for a better choice of compatibility donor/recipient, some patients still suffer from this complication.
Collapse
Affiliation(s)
- Micha Srour
- Hôpital Huriez, CHRU Lille, maladies du sang, rue Michel-Polonowski, 59000 Lille, France
| | - Amandine Fayard
- CHU de Clermont-Ferrand, service hématologie, 1, rue Lucie- et Raymond-Aubrac, 63003 Clermont-Ferrand, France
| | - Federica Giannotti
- HUG, service hématologie, rue Gabrielle-Perret-Gentil, 4, 1205 Genève, Suisse
| | - Aurelien Giltat
- CHU d'Angers, service hématologie, 4, rue Larrey, 49933 Angers cedex 9, France
| | - Sarah Guenounou
- Institut universitaire du cancer de Toulouse-Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex, France
| | - Jean Roy
- Hématologie, 5415, boulevard de l'assomption, QC H1T 2M4 Montréal, Canada
| | - Justine Schmitt
- CHU de Liège, service d'hématologie biologique et d'immuno-hématologie, Liège, Belgique
| | - Sophie Servais
- CHU de Liège, service d'hématologie clinique, Liège, Belgique
| | - Tamim Alsuliman
- AP-HP, hôpital Saint-Antoine, Sorbonne université, service d'hématologie, Paris, France.
| | - Ibrahim Yakoub Agha
- Université Lille, CHU de Lille, Infininite, Inserm U1286, 59000 Lille, France
| | - Gaelle Guillerm
- Hôpital Morvan, CHRU Brest, service d'hématologie, 2, avenue Foch, 29609 Brest cedex, France
| |
Collapse
|
22
|
Forcade E, Bacquet S, Ballot C, Capin L, Garnier F, Giraud C, Guérout-Vérité MA, Letellier C, Magnani A, Mamez AC, Nasone J, Sinayoko M, Baudoux E, Mialou V, Yakoub-Agha I, Calmels B. [Method and impact of allografts cryopreservation during the Covid-19 pandemic: guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S39-S47. [PMID: 35791975 DOI: 10.1016/j.bulcan.2022.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 03/25/2022] [Accepted: 03/30/2022] [Indexed: 10/17/2022]
Abstract
The COVID-19 pandemic disorganized the allogeneic stem cell transplantation activities all over the world, with the necessity to cryopreserve allografts to secure the procedure for both the recipient and the donor. Cryopreservation, usually anecdotal, has been used by all the French speaking centers; data collected from 24 centers were assessed in order to determine the impact of cryopreservation on the quality of allografts. Our analysis clearly demonstrates that increasing transit time (more than 48hours) is deleterious for CD34+ recovery, legitimates the slight increase of the requested CD34+ cell dose with respect to the average recovery rate as well as the importance of the quality control on the infused product.
Collapse
Affiliation(s)
- Edouard Forcade
- CHU Bordeaux, service d'hématologie clinique et thérapie cellulaire, 33000 Pessac, France
| | - Solenn Bacquet
- CHU Amiens Sud, unité de thérapie cellulaire, 80000 Amiens, France
| | - Caroline Ballot
- Parc Eurasanté, laboratoire de thérapie cellulaire, EFS Hauts-de-France Normandie site de Lille, 59120 Loos, France
| | - Lucille Capin
- CHU de la Réunion Site Sud, banque de cellules et tissus, 97448 Saint-Pierre, France
| | - Federico Garnier
- Agence de la biomédecine, direction prélèvement et greffe de CSH, 93212 Saint-Denis La Plaine, France
| | - Christine Giraud
- CHU de Poitiers, laboratoire de thérapie cellulaire EFS NVAQ site de Poitiers, service d'oncologie hématologie et thérapie cellulaire, 86021 Poitiers, France
| | | | - Catherine Letellier
- EFS Nouvelle Aquitaine site de Bordeaux, service ingénierie tissulaire et cellulaire, 33075 Bordeaux, France
| | - Alessandra Magnani
- Assistance publique-Hôpitaux de Paris, hôpital universitaire Necker-Enfants malades, laboratoire de thérapie cellulaire et génique, département de biothérapie, 75015 Paris, France
| | - Anne-Claire Mamez
- Hôpitaux universitaires de Genève, service d'hématologie, 1205 Genève, Suisse
| | - Justine Nasone
- Assistance publique-Hôpitaux de Paris, hôpital Saint-Louis, unité de thérapie cellulaire, 75010 Paris, France
| | - Mahamadou Sinayoko
- Agence de la biomédecine, direction prélèvement et greffe de CSH, 93212 Saint-Denis La Plaine, France
| | - Etienne Baudoux
- CHU de Liège, laboratoire de thérapie cellulaire et génique, 4000 Liège, Belgique
| | - Valérie Mialou
- EFS Auvergne-Rhône-Alpes, hôpital Édouard-Herriot, banque de tissus et cellules, 69003 Lyon, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, université de Lille, Inserm INFINITE U1286, 59000 Lille, France
| | - Boris Calmels
- AP-HM, Aix-Marseille université, Institut Paoli-Calmettes, centre de thérapie cellulaire, module biothérapies du centre d'investigation clinique CBT-1409, Inserm, 13009 Marseille, France.
| |
Collapse
|
23
|
Beauvais D, Castilla-Llorente C, Diral E, Sirvent A, Vandewiele A, Baruchel A, Yakoub-Agha I, Yakouben K. [Role of allogeneic hematopoietic cell transplantation after anti-CD19 CAR T-cell treatment: Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S108-S115. [PMID: 35791974 DOI: 10.1016/j.bulcan.2022.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Revised: 04/14/2022] [Accepted: 04/20/2022] [Indexed: 10/17/2022]
Abstract
The role of allogeneic hematopoietic cell transplantation (allo-HCT) after CAR T- treatment cells in hematologic malignancies is currently controversial. Prolonged remissions after several years of follow-up suggest that there is a curative effect of CAR T-cells therapy, whereas allo-HCT was previously considered the only curative treatment in relapse situation. The aim of this harmonization workshop is to detail the existing data in the literature on the feasibility of allo-HCT after CAR T-cells and to propose to consider allograft in selected patients with B-acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). In B-ALL, various intrinsic factors (inherent to the patient, to the disease, to the type of CAR T-cells) and especially various post CAR T-cells criteria (early expansion kinetics, residual disease at D28, early loss of B-cell aplasia) should lead to consider performing allo-HCT before the occurrence of a relapse. In DLBCL, although there are risk factors for relapse at diagnosis and prior to CAR T-cells therapy, response assessed by PET-CT at three months is critical and allo-HCT cannot currently be recommended in cases of complete or partial remission. In any case, if the age is appropriate for allogeneic transplantation, HLA typing should be performed before CAR T-cells treatment in order not to delay the allo-HCT project if needed.
Collapse
Affiliation(s)
- David Beauvais
- Université de Lille, CHU de Lille, service des maladies du sang, Inserm, Infinite, U1286, Lille, France.
| | | | - Elisa Diral
- Service d'onco-hématologie et greffe de moëlle, IRCCS San Raffaele, Milano, Italie
| | - Anne Sirvent
- Hôpital Arnaud-de-Villeneuve, service d'onco-hématologie pédiatrique, Montpellier, France
| | - Audrey Vandewiele
- Institut de cancérologie Lucien-Neuwirth, département d'hématologie clinique, Saint-Priest-en-Jarez, France
| | - André Baruchel
- Hôpital universitaire Robert-Debré (AP-HP) and université de Paris, department of pediatric hematology, Paris, France
| | - Ibrahim Yakoub-Agha
- Université de Lille, CHU de Lille, service des maladies du sang, Inserm, Infinite, U1286, Lille, France
| | - Karima Yakouben
- Hôpital universitaire Robert-Debré (AP-HP) and université de Paris, department of pediatric hematology, Paris, France
| |
Collapse
|
24
|
Ahmad I, Souchet L, Hamzy F, Ceballos P, Desbrosses Y, Ravinet A, Turlure P, Villate A, Borel C, Benbarkat H, Yakoub-Agha I, Guillaume T. [Cardiac complications following allogeneic hematopoietic stem cell transplantation: Recommendations of the SFGM-TC]. Bull Cancer 2023; 110:S56-S66. [PMID: 35662519 DOI: 10.1016/j.bulcan.2022.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 03/22/2022] [Accepted: 03/30/2022] [Indexed: 10/18/2022]
Abstract
Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) can lead to early cardiac complications as well as late sequelae. A cardiac evaluation is essential in the pre-transplant assessment given the patient's comorbidities and previous chemotherapy treatments received. Various thresholds of cardiac function are recommended as eligibility criteria. The rise of haplo-identical transplantation with the use of post-transplant high-dose cyclophosphamide (PT-Cy) as a prophylaxis against graft-versus-host disease (GVHD) is accompanied by a resurgence of cardiological concerns. Arrhythmias are also a concern and the list of drugs implicated in this complication is growing. The rare occurrence of cardiac GVHD has been reported, although the entity is not well defined. Finally, although long-term follow-up recommendations exist, they are not accompanied by specific targets for cardiovascular risk factors, the presence of which is nevertheless increased after HSCT. In the framework of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) practice harmonization workshops held in Lille in September 2019, the prophylaxis, the diagnostic approach and the treatments of cardiac complication following HSCT were reviewed after analysis of published studies.
Collapse
Affiliation(s)
- Imran Ahmad
- Université de Montréal, hôpital Maisonneuve-Rosemont, service d'hématologie et oncologie médicale, 5415 Boulevard de l'Assomption, Montréal, QC, H1T2M4, Canada
| | - Laetitia Souchet
- Centre hospitalier La Pitié-Salpêtrière, service d'hématologie, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - Fati Hamzy
- Hôpital Universitaire International Cheikh Zaïd, Cite al Irfane-Hay Ryad, service d'hématologie et greffe de moelle osseuse, Av. Allal al Fassi, BP 6533, Rabat, Maroc
| | - Patrice Ceballos
- Centre hospitalier Saint-Éloi, UGH hématologie, 80, avenue Augustin-Fliche, 34080 Montpellier, France
| | - Yohann Desbrosses
- CHRU Jean-Minjoz Besançon, service d'hématologie, 3, boulevard Flemming, 25030 Besançon cedex, France
| | - Aurélie Ravinet
- CHU Estaing, université d'Auvergne, service d'hématologie, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France
| | - Pascal Turlure
- CHU Dupuytren Limoges, service d'hématologie, 2, avenue Martin-Luther-King, 87000 Limoges, France
| | - Alban Villate
- CHU Bretonneau Tours, service d'hématologie et thérapie cellulaire, 2, boulevard Tonnelé, 37044 Tours cedex 9, France
| | - Cécile Borel
- Institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France
| | - Hanane Benbarkat
- Université de Montréal, hôpital Maisonneuve-Rosemont, service de cardiologie, 5415 Boulevard de l'Assomption, Montréal, QC, H1T2M4, Canada
| | - Ibrahim Yakoub-Agha
- CHU de Lille, université de Lille, service d'hématologie, Infinite, Inserm U1286, 59000 Lille, France
| | - Thierry Guillaume
- CHU de Nantes, Hôtel-Dieu, service d'hématologie clinique, 1, place Ricordeau, 44000 Nantes, France.
| |
Collapse
|
25
|
Tudesq JJ, Yakoub-Agha M, Bay JO, Courbon C, Paul F, Picard M, Pochon C, Sterin A, Vicente C, Canet E, Yakoub-Agha I, Moreau AS. [Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S116-S122. [PMID: 34895696 DOI: 10.1016/j.bulcan.2021.11.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 11/02/2021] [Accepted: 11/08/2021] [Indexed: 11/22/2022]
Abstract
The use of chimeric antigen receptor T cells (CAR-T) has increased since their approval in the treatment of several relapsed/refractory B cell malignancies. The management of their specific toxicities, such as cytokine release syndrome (CRS), tends to be better understood and well-defined. During the twelfth edition of practice harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a working group focused its work on the management of patients developing CRS following CAR-T cell therapy. A special chapter has been allocated to macrophage activation syndrome (MAS), a rare but life-threatening complication post-CAR-T. In addition to symptomatic measures and preemptive broad-spectrum antibiotics, immunomodulators such as tocilizumab and corticosteroids remain the corner stone for the treatment of CRS. Tocilizumab/corticosteroids-resistant CRS associated with haemophagocytosis markers (spleen and liver enlargement, hyperferritinaemia>10,000ng/mL, hypofibrinogenemia…) should direct the diagnosis towards an overlapping CRS/MAS. An adapted treatment will be based on high-dose IV anakinra and corticosteroids and chemotherapy with etoposide at late refractory stages. These complications and others delignate the need of close collaboration with an intensive care unit.
Collapse
Affiliation(s)
- Jean-Jacques Tudesq
- CHU Montpellier, université Montpellier, département d'hématologie clinique, Montpellier, France
| | | | - Jacques-Olivier Bay
- CHU Clermont-Ferrand, service de thérapie cellulaire et d'hématologie clinique adulte, Clermont-Ferrand, France
| | - Corinne Courbon
- Institut de cancérologie de la Loire, service d'hématologie, St Priest en Jarez, France
| | - Franciane Paul
- CHU Toulouse, service de réanimation polyvalente, IUCT-oncopole, 1, avenue Joliot-Curie, 31059 Toulouse, France
| | - Muriel Picard
- CHU Toulouse, service de réanimation polyvalente, IUCT-oncopole, 1, avenue Joliot-Curie, 31059 Toulouse, France
| | - Cécile Pochon
- CHRU de Nancy, université de Lorraine, service d'onco-hématologie pédiatrique, UMR 7365 CNRS-UL IMoPA, Vandœuvre-Lès-Nancy, France
| | - Arthur Sterin
- Hôpital La Timone Enfants, service hémato-immunologie pédiatrique, Marseille, France
| | - Céline Vicente
- CHU Toulouse, département d'hématologie, IUCT-oncopole, Toulouse, France
| | - Emmanuel Canet
- CHU de Nantes, université de Nantes, service de médecine intensive - réanimation, Nantes, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, université de Lille, hôpital Huriez, service des maladies du sang, LIRIC, INSERM U995, Lille, France
| | - Anne-Sophie Moreau
- CHU Lille, hôpital Salengro, service de médecine intensive réanimation, Lille, France.
| |
Collapse
|
26
|
Saultier P, Simonin M, Beaumais TAD, Rialland F, Alby-Laurent F, Lubnau M, Desplantes C, Jacqz-Aigrain E, Rohrlich P, Reguerre Y, Rabian F, Sirvent N, Plat GW, Petit A. [Practical management during maintenance therapy of pediatric acute lymphoblastic leukemia: Recommendations of the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE)]. Bull Cancer 2022; 109:1132-1143. [PMID: 35863954 DOI: 10.1016/j.bulcan.2022.05.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Revised: 05/17/2022] [Accepted: 05/31/2022] [Indexed: 11/24/2022]
Abstract
Maintenance therapy is the last phase of treatment for acute lymphoblastic leukemia in children and adolescents. Although maintenance therapy is associated with toxicities and specific management issues, it is an essential phase of treatment that reduces the risk of relapse. The objective of this work is to propose a guide for the initiation, administration, and monitoring of maintenance therapy, and for the management of food, schooling, leisure, community life, risk of infection and links with family medicine.
Collapse
Affiliation(s)
- Paul Saultier
- Hôpital de la Timone Enfants, APHM, service d'hématologie, immunologie et oncologie pédiatrique, Marseille, France.
| | - Mathieu Simonin
- AP-HP, hôpital Armand-Trousseau, Sorbonne université, service d'hématologie et oncologie pédiatrique, Paris, France
| | | | - Fanny Rialland
- CHU de Nantes, service d'onco-hématologie pédiatrique, Nantes, France
| | - Fanny Alby-Laurent
- AP-HP, hôpital Armand-Trousseau, Sorbonne université, service d'hématologie et oncologie pédiatrique, Paris, France
| | - Marion Lubnau
- CHU de Nancy, service d'onco-hématologie pédiatrique, Nancy, France
| | | | - Evelyne Jacqz-Aigrain
- AP-HP, hôpital Saint-Louis, département de pharmacologie et pharmacogénétique, Paris, France
| | - Pierre Rohrlich
- CHU de Nice, service d'hématologie pédiatrique, Nice, France
| | - Yves Reguerre
- CHU de la Réunion, service d'hémato-oncologie pédiatrique, Réunion, France
| | - Florence Rabian
- AP-HP, hôpital Saint-Louis, service d'hématologie adolescents et jeunes adultes, Paris, France
| | - Nicolas Sirvent
- CHU de Montpellier, service d'hématologie et oncologie pédiatrique, Montpellier, France
| | - Geneviève Willson Plat
- CHU de Toulouse, service d'hématologie oncologie et immunologie pédiatrique, Toulouse, France
| | - Arnaud Petit
- AP-HP, hôpital Armand-Trousseau, Sorbonne université, service d'hématologie et oncologie pédiatrique, Paris, France
| |
Collapse
|
27
|
Paul F, Vicente C, Courbon C, Moreau AS, Picard M, Pochon C, Sterin A, Tudesq JJ, Yakoub-Agha M, Bay JO, Yakoub-Agha I. [Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S90-S97. [PMID: 34876272 DOI: 10.1016/j.bulcan.2021.11.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Revised: 11/05/2021] [Accepted: 11/08/2021] [Indexed: 11/29/2022]
Abstract
Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms with cytokine release syndrome. The risk factors for infection include the malignant underlying disease and its multiple treatments, and an immunosuppressive state induced by CAR-T cells themselves and the treatment of their complications. During the twelfth edition of practice harmonization workshops of the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), a working group focused its work on the management of post-CAR infectious complications. In this review we discuss anti-infection prophylaxis and vaccination of patients undergoing CAR T-cell therapy as well as a special chapter for the specific case of COVID-19. These recommendations apply to commercial CAR-T cells, in order to guide strategies for the management and prevention of infectious complications associated with this new therapeutic approach.
Collapse
Affiliation(s)
- Franciane Paul
- CHU de Montpellier, hôpital Saint-Eloi, département d'hématologie clinique, 80, avenue Augusin-Fliche, 34090 Montpellier, France
| | - Céline Vicente
- CHU de Toulouse, service d'hématologie, IUCT-oncopole, 1, avenue Joliot-Curie, 31059 Toulouse, France
| | - Corinne Courbon
- Institut de cancérologie de la Loire Lucien Neuwirth, service d'hématologie, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - Anne-Sophie Moreau
- CHU de Lille, hôpital Salengro, service de médecine intensive réanimation, rue Emile-Laine, 59037 Lille, France
| | - Muriel Picard
- CHU de Toulouse, service de réanimation polyvalente, IUCT-oncopole, 1, avenue Joliot-Curie, 31059 Toulouse, France
| | - Cécile Pochon
- CHRU Nancy Brabois, service d'onco-hématologie pédiatrique, 5, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France; Université de Lorraine, UMR7365 CNRS-UL IMoPA, campus biologie santé, 9, avenue de la Forêt-de-Haye, 54505 Vandœuvre-lès-Nancy, France
| | - Arthur Sterin
- Hôpital La Timone enfants, service hémato-immunologique pédiatrique, 246, rue Saint-Pierre, 13005 Marseille, France
| | - Jean-Jacques Tudesq
- CHU de Montpellier, hôpital Saint-Eloi, département d'hématologie clinique, 80, avenue Augustin-Fliche, 34090 Montpellier, France
| | - Mathilde Yakoub-Agha
- CHU Amiens-Picardie, service de médecine intensive réanimation, 1, rond-point du professeur Christian-Cabrol, 80054 Amiens, France
| | - Jacques-Olivier Bay
- CHU de Clermont-Ferrand, service de thérapie cellulaire et d'hématologie clinique adulte, site Estaing, 1, place Lucie-Aubrac, 63000 Clermond-Ferrand, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, université de Lille, maladies du sang-unité d'immunothérapie cellulaire, Inserm U1286, Infinite, 59000 Lille, France.
| |
Collapse
|
28
|
Cheron N, Riou M, Babouche I, Chevallier N, Aimee Dann MP, Delorme J, Denis V, Girard I, Godin S, Tardieu L, Yakoub-Agha I. [Therapeutic Education Programs for the Patient (ETP) undergoing an allogeneic hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S26-S29. [PMID: 34865834 DOI: 10.1016/j.bulcan.2021.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Revised: 09/23/2021] [Accepted: 09/24/2021] [Indexed: 11/24/2022]
Abstract
Patients undergoing an allogeneic hematopoietic cell transplant (allo-HCT) need to understand and adhere to the transplant process as well as post-transplant follow-up requirements. A working group has met during the eleventh edition of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) Practice Harmonization Workshops. The analysis of a survey that was sent to several transplant centers belonging to the SFGM-TC has been used as a milestone to this article. While, post-transplant medical follow-up was comparable from one center to another, nursing care was found to lack harmonization between centers, although, all patients would receive therapeutic education at one time or another regarding potential transplant-related complications. A few centers in France has established a therapeutic education program that was approved by French health authorities. The aim of this work was to set up guidelines to help centers establishing such a program in well-harmonized way.
Collapse
Affiliation(s)
- Nathalie Cheron
- Centre hospitalier de Bligny, 91640 Briis-sous-Forges, France.
| | | | | | | | | | | | | | | | | | | | - Ibrahim Yakoub-Agha
- CHU de Lille, université de Lille, Inserm U1286, Infinite, 59000 Lille, France.
| |
Collapse
|
29
|
Pochon C, Courbon C, Bay JO, Moreau AS, Paul F, Picard M, Sterin A, Tudesq JJ, Vicente C, Yakoub-Agha M, Yakoub-Agha I. [Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)]. Bull Cancer 2021; 108:S98-S103. [PMID: 34802718 DOI: 10.1016/j.bulcan.2021.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 10/15/2021] [Indexed: 10/19/2022]
Abstract
CAR-T cells are an innovative treatment for an increasing number of patients, particularly since the extension of their indication to mantle lymphoma and multiple myeloma. Several complications of CAR T-cell therapy, that were first described as exceptional, have now been reported in series of patients, since its first clinical use in 2011. Among them, cardiac complications, delayed cytopenias, acute and chronic Graft versus Host Disease, and tumoral lysis syndrome are recognized as specific potent complications following CAR T-cells infusion. During the twelfth edition of practice harmonization workshops of the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), a working group focused its work on the management of these complications with focuses the epidemiology, the physiopathology and the risk factors of these 4 side effects. Our recommendations apply to commercial CAR-T cells, in order to guide strategies for the management of complications associated with this new therapeutic approach.
Collapse
Affiliation(s)
- Cécile Pochon
- CHRU de Nancy, service d'onco-hématologie pédiatrique, 54500 Vandœuvre-Lès-Nancy, France; Université de Lorraine, UMR 7365 CNRS-UL IMoPA, campus biologie santé, 9, avenue de la Forêt-de-Haye, 54505 Vandœuvre-Lès-Nancy, France.
| | - Corinne Courbon
- Institut de cancérologie de la Loire, service d'hématologie, 42270 Saint-Priest-en-Jarez, France
| | - Jacques-Olivier Bay
- CHU de Clermont-Ferrand, service de thérapie cellulaire et d'hématologie clinique adulte, site Estaing, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France
| | - Anne-Sophie Moreau
- Hôpital Salengro, CHU de Lille, service de médecine intensive réanimation, rue Émile-Laine, 59037 Lille cedex, France
| | - Franciane Paul
- Université Montpellier, CHU de Montpellier, département d'hématologie clinique, Montpellier, France
| | - Muriel Picard
- CHU de Toulouse, réanimation polyvalente IUCT-oncopole, Toulouse, France
| | - Arthur Sterin
- Hôpital La Timone Enfants, service hémato-immunologie pédiatrique, 13005 Marseille, France
| | - Jean-Jacques Tudesq
- Université Montpellier, CHU de Montpellier, département d'hématologie clinique, Montpellier, France
| | - Céline Vicente
- CHU de Toulouse, service d'hématologie, IUCT-oncopole, 1, avenue Joliot-Curie, 31059 Toulouse, France
| | | | | |
Collapse
|
30
|
Guenounou S, Aubrun C, Brancillon N, Bemben D, Chauvel C, Hounmenou N, Magro L, Porcheron S, Poullain M, De Bentzmann N, Gargallo G, Le Bars L, Mercier L, Yakoub-Agha I, Paul F. [National patient follow-up care logbook: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S87-S89. [PMID: 34756418 DOI: 10.1016/j.bulcan.2021.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 07/07/2021] [Accepted: 07/09/2021] [Indexed: 11/25/2022]
Abstract
In an attempt to harmonize clinical practices among francophone hematopoietic stem cell transplantation centers, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held its eleventh annual workshop series in September 2020 in Lille. This event brought together practitioners from across Europe. Our article discusses the updates and modifications for the 2021 version of the national patient follow-up care logbook.
Collapse
Affiliation(s)
- Sarah Guenounou
- CHU de Toulouse, institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France.
| | - Clotilde Aubrun
- CHU Ambroise-Paré, coordination Greffe-Hémato, 2, boulevard Kennedy, 7000 Mons, Belgique
| | - Nelly Brancillon
- CHU d'Angers, service d'hématologie, 4, rue Larrey, 49933 Angers, France
| | - Daphnée Bemben
- CHU de Lille, service d'hématologie, rue Michel-Polonovski, 59000 Lille, France
| | - Céline Chauvel
- Gustave-Roussy, service d'hématologie greffe, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - Nadège Hounmenou
- CHU de Nantes, hôpital enfant-adolescent, service d'onco-hématologie pédiatrique, quai Moncousu, 5(e) étage, 44093 Nantes cedex 1, France
| | - Leonardo Magro
- CHU de Lille, service d'hématologie, rue Michel-Polonovski, 59000 Lille, France
| | - Sophie Porcheron
- CLCC Henri-Becquerel, unité de soins intensifs hématologie, 1, rue d'Amiens, 76038 Rouen cedex, France
| | - Marie Poullain
- CHU de Toulouse, institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France
| | - Natacha De Bentzmann
- CHU de Toulouse, institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France
| | - Guillaume Gargallo
- CHU de Bordeaux, centre François-Magendie, service d'hématologie clinique et thérapie cellulaire, 33604 Pessac, France
| | - Laetitia Le Bars
- CHU Rennes Pontchaillou, hématologie clinique adultes, BMT HC avenue Henri-Le-Guilloux, 35033 Rennes cedex 09, France
| | - Lara Mercier
- CHU de Toulouse, institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France
| | | | - Franciane Paul
- CHU de Montpellier, Service d'hématologie, 80, avenue Augustin-Fliche, 34095 Montpellier, France
| |
Collapse
|
31
|
Lansiaux P, Loisel S, Castilla-Llorente C, Fontenille C, Kabdani S, Marjanovic Z, Pugnet G, Puyade M, Robert E, Terriou L, Ait Abdallah N, Maria ATJ, Michel L, Tréton X, Yakoub-Agha I, Farge D. [Autologous hematopoietic cells for severe autoimmune diseases: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) for immune monitoring and biobanking]. Bull Cancer 2021; 108:S72-S81. [PMID: 34272057 DOI: 10.1016/j.bulcan.2021.03.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 02/25/2021] [Accepted: 03/02/2021] [Indexed: 12/29/2022]
Abstract
Autologous hematopoietic cell transplantation (AHCT) is a new treatment option for patients with severe autoimmune diseases (AD), based on the use of intensive or myeloablative chemotherapy to eradicate the pathogenic autoreactive immune cells and to allow the installation of a new and tolerant immune system during immune reconstitution process. Immune reconstitution analysis after AHCT is required for patients clinical follow-up and to further identify biological and immunological markers of the clinical response to develop individualized AHCT protocols. These MATHEC-SFGM-TC good clinical practice guidelines were developed by a multidisciplinary group of experts including members of the french reference center for stem Cell Therapy in Auto-immune Diseases (MATHEC), hematologists from the French speaking Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and experts in immune monitoring and biobanking. The objectives are to provide practical recommandations for immune monitoring and biobanking of samples in patients with AD undergoing AHCT, for routine care purposes and investigational studies.
Collapse
Affiliation(s)
- Pauline Lansiaux
- AP-HP, hôpital Saint-Louis, unité de médecine interne (UF 04): CRMR MATHEC, Maladies auto-immunes et thérapie cellulaire, Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), 75010 Paris, France; Université de Paris, Institut de recherche Saint-Louis, recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France
| | - Séverine Loisel
- CHU de Rennes, établissement français du sang Bretagne, SITI, 35000 Rennes, France
| | - Cristina Castilla-Llorente
- Gustave-Roussy Cancer Center, département d'hématologie, 114, rue Edouard-Vaillant, 94800 Villejuif, France
| | - Claire Fontenille
- Institut Paoli-Calmettes, Association CRYOSTEM, 13009 Marseille, France
| | - Sarah Kabdani
- EFS HFNO site de Lille, unité de thérapie cellulaire, parc Eurasanté, 20, avenue Pierre-Mauroy, 59373 Loos, France
| | - Zora Marjanovic
- AP-HP, hôpital Saint-Antoine, service d'hématologie, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - Grégory Pugnet
- CHU de Rangueil, service de médecine interne et immunologie clinique, 1, avenue du Professeur Jean-Poulhès, 31059 Toulouse cedex 9, France
| | - Mathieu Puyade
- CHU de Poitiers, service de médecine interne, 2, rue de la Miletrie, 86021 Poitiers, France; CHU de Poitiers, CIC-1402, 2, rue de la Miletrie, 86021 Poitiers, France
| | - Emilie Robert
- Institut Paoli-Calmettes, Association CRYOSTEM, 13009 Marseille, France
| | - Louis Terriou
- Hôpital Claude-Huriez, CHRU Lille, service de médecine interne et immunologie clinique, rue Michel-Polonovski, 59000 Lille, France
| | - Nassim Ait Abdallah
- AP-HP, hôpital Saint-Louis, unité de médecine interne (UF 04): CRMR MATHEC, Maladies auto-immunes et thérapie cellulaire, Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), 75010 Paris, France; Université de Paris, Institut de recherche Saint-Louis, recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France
| | - Alexandre Thibault Jacques Maria
- CHRU de Montpellier, hôpital Saint-Éloi, médecine interne : maladies multi-organiques de l'adulte, Inserm U1183 IRMB, 34295 Montpellier cedex 5, France
| | - Laure Michel
- CHU de Rennes, seervice de neurologie, Rennes, France
| | - Xavier Tréton
- Hôpital Beaujon, université de Paris, service de gastro-entérologie, MICI et Assistance Nutritive, DMU DIGEST, 100, boulevard Leclerc, 92110 Clichy, France
| | | | - Dominique Farge
- AP-HP, hôpital Saint-Louis, unité de médecine interne (UF 04): CRMR MATHEC, Maladies auto-immunes et thérapie cellulaire, Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France MATHEC (FAI2R), 75010 Paris, France; Université de Paris, Institut de recherche Saint-Louis, recherche clinique appliquée à l'hématologie, EA3518, 75010 Paris, France; McGill University, Department of Medicine, H3A 1A1, Montreal, Canada.
| |
Collapse
|
32
|
Rubio MT, Varlet P, Allain V, Ballot C, Cuffel A, Deschamps M, Ferrand C, Foguenne J, Forcade E, Huynh A, Guihot A, Latouche JB, Lemarie C, Martinroche G, Morin F, Nguyen S, Schmit K, Servais S, Simonetta F, Yakoub-Agha I, Caillat Zucman S. [Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S53-S64. [PMID: 34253335 DOI: 10.1016/j.bulcan.2021.04.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 03/24/2021] [Accepted: 04/09/2021] [Indexed: 12/25/2022]
Abstract
CAR-T cells represent a new anti-tumor immunotherapy which has shown its clinical efficacy in B-cell malignancies. The results of clinical trials carried out in this context have shown that certain immunological characteristics of patients before (at the time of apheresis) and after the administration of the treatment, or of the CAR-T cells themselves, are correlated with the response to the treatment or to its toxicity. However, to date, there are no recommendations on the immunological monitoring of patients treated in real life. The objectives of this workshop were to determine, based on data from the literature and the experience of the centers, the immunological analyses to be carried out in patients treated with CAR-T cells. The recommendations relate to the characterization of the patient's immune cells at the time of apheresis, the characterization of the injected CAR-T cells, as well as the monitoring of the CAR-T cells and other parameters of immune reconstitution in the patient after administration of the treatment. Harmonization of practices will allow clinical-biological correlation studies to be carried out in patients treated in real life with the aim of identifying factors predictive of response and toxicity. Such data could have a major medico-economic impact by making it possible to identify the patients who will optimally benefit from these expensive treatments.
Collapse
Affiliation(s)
- Marie Thérèse Rubio
- CHRU Nancy, Hopital Brabois, Biopole de l'Université de Lorraine, CNRS UMR 7563 IMoPa, Service d'hématologie, 54500 Vandoeuvre-les-Nancy, France.
| | - Pauline Varlet
- Université de Lille, CHU de Lille, Laboratoire d'Immunologie, LIRIC, INSERM U995, 59000 Lille, France
| | - Vincent Allain
- Université de Paris, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d'Immunologie, France
| | - Caroline Ballot
- Établissement Français du Sang Hauts-de-France, Unité de Thérapie Cellulaire EFS site de Lille, Normandie, France
| | - Alexis Cuffel
- Université de Paris, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d'Immunologie, France
| | - Marina Deschamps
- Ets Bourgogne Franche-Comté, INSERM UMR1098, 25020 Besançon, France
| | | | - Jacques Foguenne
- CHU de Liège, domaine universitaire du Sart-Tilman B35, Laboratoire d'Hématologie Biologique, Unilab Lg, 4000 Liège, Belgique
| | - Edouard Forcade
- CHU Bordeaux, service d'hématologie clinique et thérapie cellulaire, 33000 Bordeaux, France
| | - Anne Huynh
- IUCT Oncopole, service d'hématologie, Toulouse, France
| | - Amélie Guihot
- Hôpital Pitié-Salpêtrière, AP-HP, département d'immunologie, 75013, Paris, France
| | - Jean-Baptiste Latouche
- CHU de Rouen, UMR Université/Inserm U1234, Laboratoire d'Immunologie et Biothérapies, France
| | - Claude Lemarie
- Institut Paoli-Calmettes, and Inserm CBT 1409, Centre d'Investigations Cliniques en Biothérapie, Marseille, France
| | - Guillaume Martinroche
- Centre Hospitalier Universitaire de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, place Amélie Raba Léon, 33076 Bordeaux, France
| | - Florence Morin
- Université de Paris, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d'Immunologie, France
| | - Stéphanie Nguyen
- Hôpital Pitié-Salpêtrière, AP-HP, service d'hématologie 75013, Paris, France
| | - Kathleen Schmit
- CHU de Liège, domaine universitaire du Sart-Tilman B35, Laboratoire d'Hématologie Biologique, Unilab Lg, 4000 Liège, Belgique
| | - Sophie Servais
- Université de Liège, CHU de Liège, service d'hématologie, 4000 Liège, Belgique
| | - Federico Simonetta
- University of Geneva, Division of Hematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine and Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, Geneva, Suisse
| | | | - Sophie Caillat Zucman
- Université de Paris, Hôpital Saint-Louis, AP-HP Nord, Laboratoire d'Immunologie, France
| |
Collapse
|
33
|
Yafour N, Bekadja MA, Chevallier P, Cabrera Q, Coman T, Elkababri M, Hamzy F, Quessar A, Laamiri A, Pochon C, Yakoub-Agha I, Harif M. [Establishment of Hematopoietic cell transplantation program in developing countries : Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer 2021; 108:S10-S19. [PMID: 34247762 DOI: 10.1016/j.bulcan.2021.02.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 02/23/2021] [Accepted: 02/24/2021] [Indexed: 12/26/2022]
Abstract
Hematopoietic cell transplantation (HCT) is the curative treatment for many malignant and non-malignant blood disorders and some solid cancers. However, transplant procedures are considered tertiary level care requiring a high degree of technicality and expertise and generating very high costs for hospital structures in developing countries as well as for patients without health insurance. During the 11th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines, for developing the transplant activity in emerging countries. Access to infrastructure must comply with international standards and therefore requires a hospital system already in place, capable of accommodating and supporting the HCT activity. In addition, the commitment of the state and the establishment for the financing of the project seems essential.
Collapse
Affiliation(s)
- Nabil Yafour
- Établissement hospitalier et universitaire 1(er) Novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn Rochd, université d'Oran 1, Ahmed Ben Bella, faculté de médecine, 31000 Oran, Algérie.
| | - Mohamed Amine Bekadja
- Établissement hospitalier et universitaire 1(er) Novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn Rochd, université d'Oran 1, Ahmed Ben Bella, faculté de médecine, 31000 Oran, Algérie
| | - Patrice Chevallier
- CHU de Nantes, service d'hématologie clinique, Hôtel-Dieu, place Alexis-Ricordeau, 44035 Nantes, France
| | - Quentin Cabrera
- CHU Réunion Sud, service d'hématologie clinique, Site de Saint Pierre, La Réunion, France.
| | - Tereza Coman
- Institut Gustave-Roussy, département d'hématologie, 114, rue Edouard-Vaillant, Villejuif, France
| | - Maria Elkababri
- Hôpital d'enfants de Rabat, service d'hématologie et oncologie pédiatrique, université Mohammed V de Rabat, Maroc
| | - Faty Hamzy
- Hôpital Cheikh Zaïd universitaire international, service d'hématologie et greffe, Cite al Irfane-Hay Ryad avenue Allal al Fassi, 10000 Rabat, Maroc
| | - Asmaa Quessar
- Hôpital 20-Août de Casablanca, 6, rue Lahssen Elaarjoun, Casablanca 20250, Maroc
| | - Amal Laamiri
- Hôpital Cheikh Zaïd universitaire international, service d'hématologie et greffe, Cite al Irfane-Hay Ryad avenue Allal al Fassi, 10000 Rabat, Maroc
| | - Cécile Pochon
- Hôpital Brabois, service d'hémato-oncologie pédiatrique, rue du Morvan, 54500 Vandœuvre-les-Nancy, France
| | | | - Mhamed Harif
- Centre Hospitalier Tanger-Tétouan-Al Hoceima (Tanger), faculté de médecine et de pharmacie, Casablanca, Maroc
| |
Collapse
|
34
|
Bay JO, Beguin Y, Carpentier A, Dard C, Guillaume T, Labussiere-Wallet H, Lacassagne MN, Sauze S, Yakoub-Agha I, Chalandon Y. [How to deal with an unexpected event that could alter the normal activity of cellular therapy? Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S20-S25. [PMID: 34215432 PMCID: PMC8242103 DOI: 10.1016/j.bulcan.2021.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 05/05/2021] [Accepted: 05/06/2021] [Indexed: 11/30/2022]
Abstract
L’épidémie mondiale de SARS-CoV-2 (COVID-19) a rapidement impacté l’ensemble de l’activité de thérapie cellulaire à travers le monde. Non seulement, cet événement inattendu était une menace pour les patients ayant déjà reçu une greffe de cellules hématopoïétiques ou une autre thérapie cellulaire telle que les cellules CAR-T, mais également, il a été responsable d’une désorganisation des activités de thérapie cellulaire en raison de la dangerosité du virus et du manque de données scientifiques solides quant au mangement des patients et des donneurs. La Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) a consacré un atelier pour produire des recommandations utiles en cas de survenu d’un tel événement dans le but d’harmoniser les actions de tous les acteurs impliqués pour que l’on puisse faire face collectivement dans le futur aux défis qui pourraient menacer notre activité. Ce travail n’est pas spécifiquement dédié à l’épidémie de SARS-CoV-2, mais cette dernière a été utilisée comme un exemple concret d’un événement inattendu pour construire nos reflétions et nos recommandations.
Collapse
Affiliation(s)
- Jacques Olivier Bay
- CHU Clermont-Ferrand, Service de thérapie cellulaire et d'hématologie clinique adulte, 1 place Lucie Aubrac, 63000 Clermont-Ferrand, France.
| | - Yves Beguin
- CHU de Liège et Université de Liège, Service d'Hématologie, Liège, Belgique
| | - Alexandre Carpentier
- Laboratoire de Thérapie Cellulaire, Tour-4E du CHU de Liège, route 1159, Domaine du Sart-Tilman, 4000 Liège, Belgique
| | - Céline Dard
- Laboratoire d'histocompatibilité, EFS Auvergne Rhône Alpes, Site de la Tronche, 29, avenue du Maquis du Grésivaudan, 38701 La Tronche cedex
| | - Thierry Guillaume
- CHU de Nantes, Service d'hématologie clinique, Hôtel Dieu, 1, place Ricordeau, 44000 Nantes, France
| | - Hélène Labussiere-Wallet
- Hôpital Lyon Sud, Service d'hématologie clinique, Hospices Civils de Lyon, Pierre Bénite, France
| | - Marie Noëlle Lacassagne
- Laboratoire de thérapie cellulaire CHU Amiens Picardie, 1, rond point du professeur Christian Cabrol, 80054 Amiens cedex 01, France
| | - Séverine Sauze
- CHU d'Angers, Service d'hématologie, rue Larrey, 49000 Angers, France
| | | | - Yves Chalandon
- Hôpitaux Universitaires de Genève et Faculté de Médecine, Université de Genève, Service d'hématologie, département d'oncologie, Genève, Suisse
| |
Collapse
|
35
|
Polomeni A, Prod'homme C, Ainaoui M, Bellec A, Berr A, Bonneau J, Charbonnier A, Coiteux V, de Berranger E, Descamps T, Gire M, Goncalves M, Ruscassié A, Yakoub-Agha I, Borel C. [Palliative care in hematopoietic stem-cell transplanted patients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S1-S9. [PMID: 34176584 DOI: 10.1016/j.bulcan.2021.01.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 01/21/2021] [Accepted: 01/22/2021] [Indexed: 11/17/2022]
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT), the only curative therapy for numerous hematological malignancies, carries a significant risk of morbidity and mortality. The patients and families' expectations regarding the procedure, the prognosis uncertainties, as well as the existence of potential new therapeutic possibilities, lead to frequent use of intensive care. Even though the transplant physicians are highly skilled in acute care, their knowledge of palliative approach is limited, making the use of palliative care insufficient and often late. By promoting reflection on the proportionality of care and the patients' quality of life, palliative care may contribute to the allo-HCT patients management. Nevertheless, obstacles to this approach remain. The objective of this work is to propose recommendations to promote the implementation of palliative care into transplant units.
Collapse
Affiliation(s)
- Alice Polomeni
- AP-HP, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du Faubourg Saint-Antoine, 75011 Paris, France.
| | - Chloé Prod'homme
- CHRU de Lille, clinique de médecine palliative, hôpital Calmette, 2, avenue Oscar-Lambret, 59037 Lille, France
| | - Malika Ainaoui
- CHRU de Lille, service des maladies du sang, avenue Michel-Polonovski, 59037 Lille cedex, France
| | - Adeline Bellec
- CHU de Rennes, service d'hématologie clinique, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France
| | - Aurélie Berr
- Institut de cancérologie Strasbourg Europe, service d'hématologie, 17, rue Albert-Calmette, BP 23025, 67033 Strasbourg cedex, France
| | - Jacinthe Bonneau
- CHU de Rennes, hôpital Sud, service d'hématologie oncologie et greffe de moelle pédiatrique, 16, boulevard de Bulgarie, 35203 Rennes cedex 2, France
| | - Amandine Charbonnier
- CHU-groupe hospitalier Amiens-Sud, service d'hématologie clinique et thérapie cellulaire, 90054 Amiens cedex 1, France
| | - Valérie Coiteux
- CHRU de Lille, service des maladies du sang, avenue Michel-Polonovski, 59037 Lille cedex, France
| | - Eva de Berranger
- CHRU de Lille, hôpital Jeanne de Flandres, hématologie pédiatrique, avenue Eugène Avinée, 59037 Lille cedex, France
| | - Thomas Descamps
- CHRU de Lille, service des maladies du sang, avenue Michel-Polonovski, 59037 Lille cedex, France
| | - Marion Gire
- Institut de cancérologie Lucien Neuwirth, service d'hématologie, 104, avenue Albert-Raymond, 42270 Saint-Priest-en-Jarez, France
| | - Murielle Goncalves
- A.P.H.P., hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du Faubourg Saint-Antoine, 75011 Paris, France
| | - Agnès Ruscassié
- Institut universitaire du cancer de Toulouse, département des soins de support, 1, avenue Irène Joliot-Curie, 31059 Toulouse cedex, France
| | | | - Cécile Borel
- Institut universitaire du cancer de Toulouse, service d'hématologie, 1, avenue Irène Joliot-Curie, 31059 Toulouse cedex, France
| |
Collapse
|
36
|
[Follow-up logbook of patients receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S39-S44. [PMID: 33992416 DOI: 10.1016/j.bulcan.2021.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 02/02/2021] [Accepted: 02/15/2021] [Indexed: 11/21/2022]
Abstract
In the attempt to harmonize practices and to create a national CAR T-cells patient follow-up care logbook, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) worked on the design of a common national care logbook during the eleventh annual workshops of practice harmonization. The purpose of this logbook was to explain the different phases of the treatment with CAR T-cells and to allow useful monitoring for the patient. This logbook can be also helpful for the different healthcare professionals involved in the patient care. This national logbook will provide important information to the patients undergoing CAR T-cell therapy. In addition to the information booklets already in use, the national logbook simplifies patient follow-up by recording various medical appointments and possible adverse events. This work has been based on tools that had already been put in place by different CAR T-cell centers. This national logbook represents a common "base" and is prepared in the form of index cards to be classified using dividers in a binder. Therefore, the national care logbook will be adaptable for local procedures and guidelines of each center.
Collapse
|
37
|
de Berranger E, Charbonnier A, Davy E, Dendonker C, Denis V, Desmier D, Farrugia C, Guenounou S, Guilbert Y, Jost E, L'hostette A, Rialland F, Taque S, Yafour N, Seguy D, Yakoub Agha I. [Management of patients developing acute gastro-intestinal graft-versus-host-disease: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S30-S38. [PMID: 33966887 DOI: 10.1016/j.bulcan.2021.01.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 12/28/2020] [Accepted: 01/05/2021] [Indexed: 10/21/2022]
Abstract
Graft-versus-host disease (GVHD) is the most common complication after allogeneic hematopoietic cell transplantation (allo-HCT) with a frequency range of 30% to 50%. GVH is the leading cause of non-relapse-related deaths and a cause early mortality. Gastro-intestinal (GI) GVH results in digestive manifestations that involve the small intestine and the colon. The patient may then have diarrhea, intestinal bleeding, abdominal pain but also clinical signs such as nausea and vomiting may lead to anorexia. GI-GVHD promotes undernutrition as well as significant losses of vitamins and trace elements. In the case of post-transplant diarrhea, differential diagnosis can include GI-GVHD, infection and drug toxicity. Although, corticosteroids w/wo calcineurin inhibitors represent the standard of care in first line treatment, there is no consensus regarding salvage therapy in case of corticoresistant GI-GVH. In addition, assessment of early nutritional status would help combating undernutrition, which is an independent risk factor for mortality in patients with GI-GVHD. In this workshop of the Fancophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) we focused on the management of patients developing GI-GVHD following allo-HCT.
Collapse
Affiliation(s)
- Eva de Berranger
- CHU de Lille, service d'hématologie pédiatrique, avenue Eugène-Avinée, 59037 Lille cedex, France.
| | - Amandine Charbonnier
- CHU d'Amiens, groupe hospitalier Amiens Sud, hématologie clinique et thérapie cellulaire, 80034 Amiens cedex 1, France
| | - Elise Davy
- CHU d'Angers, unité protégée, hématologie, 4, rue Larrey, 49100 Angers, France
| | - Caroline Dendonker
- CHU de Lille, service nutrition, avenue Oscar-Lambret, 59000 Lille, France
| | - Virginie Denis
- CHU de Rouen, service d'onco-hématologie pédiatrie, 1, rue de Germont, 76000 Rouen, France
| | - Déborah Desmier
- CHU de Poitiers, onco-hématologie clinique et thérapie cellulaire, 2, rue de la Milétrie, 86000 Poitiers, France
| | - Carole Farrugia
- CHU de Montpellier Saint-Éloi, service onco-hématologie, 80, avenue Augustin-Fliche, 34000 Montpellier, France
| | - Sarah Guenounou
- Institut universitaire du cancer de Toulouse Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France
| | - Yoann Guilbert
- Institut Paoli-Calmettes, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Edgar Jost
- University Hospital RWTH Aachen, Pauwelsstraße 30, 52074 Aix-La-Chapelle, Allemagne
| | - Alexandra L'hostette
- CHU d'ADV Montpellier, service onco-hématologie pédiatrique, 371, avenue du doyen Gaston-Guiraud, 34000 Montpellier, France
| | - Fanny Rialland
- Service d'onco-hématologie pédiatrique, HME, 7, quai Moncousu, 44093 Nantes cedex 01, France
| | - Sophie Taque
- CHU de Rennes, département de pédiatrie, 16, boulevard de Bulgarie, 35000 Rennes, France
| | - Nabil Yafour
- Établissement hospitalier et universitaire 1(er) novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166, 31000 Ibn-Rochd, Oran, Algérie; Université d'Oran 1, Ahmed-Ben-Bella, faculté de médecine, Oran, Algérie
| | - David Seguy
- Université de Lille, CHU de Lille, service endocrinologie, diabétologie, maladies métaboliques et nutrition, LIRIC, Inserm U995, 59000 Lille, France
| | - Ibrahim Yakoub Agha
- Université de Lille, CHU de Lille, Inserm U1286, Infinite, 59000 Lille, France
| |
Collapse
|
38
|
Dubois V, Amokrane K, Crocchiolo R, Fort M, Guillaume N, Kennel A, Michiels S, Ralazamahaleo M, Rouzaire PO, Yakoub-Agha I, Faucher C. [Definition and standardization of histocompatibility requests depending on patient course and donor type: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society of Histocompatibility and Immunogenetics (SFHI)]. Bull Cancer 2021; 108:S45-S52. [PMID: 33966883 DOI: 10.1016/j.bulcan.2021.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 01/27/2021] [Accepted: 01/27/2021] [Indexed: 10/21/2022]
Abstract
Standardization of histocompatibility tests for allogeneic hematopoietic cell transplants, harmonization of information transmitted to clinicians are part of quality improvement and optimization of human and economic resources. New HLA typing technologies provide high-resolution information within a reasonable time frame. Knowledge of high-resolution HLA typing for the patient and their relatives is essential for a better interpretation of compatibilities. HLA-DPB1 typing must be considered in transplant field regardless of the donor type. The benefits of using search and match programs are considerable. It saves time and reduces additional typing costs by providing rapid information about the likelihood to identify a matched unrelated donor. A backup therapy considering alternative cell sources or treatment can therefore be quickly implemented. The importance of knowledge and consideration of patient immunization for donor choice was explored in previous workshops of the SFGM-TC (2018 and 2019). The published recommendations remain applicable. The routine follow-up protocol and in case of desensitization will be detailed here. This harmonization must be accompanied by the standardization of information to be returned to the clinician regarding the donor finding possibilities for the patient. This will guarantee a similar quality level in every center.
Collapse
Affiliation(s)
- Valérie Dubois
- Établissement Français du Sang, laboratoire Histocompatibilité, 69150 Décines, France.
| | - Kahina Amokrane
- Hôpital Saint Louis, laboratoire d'Immunologie Histocompatibilité, 75010 Paris, France
| | - Roberto Crocchiolo
- Servizio di Immunoematologia e Medicina Trasfusionale, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italie
| | - Marylise Fort
- CHU de Toulouse, laboratoire d'Histocompatibilité, Hôpital de RANGUEIL, 31059 Toulouse, France
| | | | - Anne Kennel
- Établissement Français du Sang, laboratoire Histocompatibilité, 42000 Saint-Étienne, France
| | - Sandra Michiels
- Institut Jules Bordet, Département d'Hématologie, Université Libre de Bruxelles, 1000 Bruxelles, Belgique
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, laboratoire d'Immunologie-Immunogénétique, 33076 Bordeaux
| | - Paul-Olivier Rouzaire
- CHU de Clermont-Ferrand, Service d'Histocompatibilité et d'Immunogénétique, Université Clermont Auvergne, EA 7453 CHELTER, 63003 Clermont-Ferrand
| | | | - Catherine Faucher
- Direction prélèvements et greffes de CSH, Direction médicale et scientifique, Agence de la biomédecine, 93212 St-Denis, La Plaine
| |
Collapse
|
39
|
[A standardized medical report template for CAR T-Cell therapy patients: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S82-S86. [PMID: 33933288 DOI: 10.1016/j.bulcan.2021.01.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 01/31/2021] [Indexed: 11/30/2022]
Abstract
Tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™) are the first representatives of a new class of gene therapies produced by ex-vivo genetic modification of human autologous T lymphocytes, now using viral vectors. In 2020, there are three independent CAR-T cell databases in France: DESCAR-T (database supported by LYSARC, GRAALL and the IFM), ProMISe (EBMT database) and ATIH (database of the Agence Technique de l'Information sur l'Hospitalisation). Only the EBMT database is common to France and the French-speaking countries that are members of the SFGM-TC. In 2019, a workshop was held to draft a manual for entering data specific to CAR-T cells in the EBMT ProMISe database. As a follow-up to this article, we present a medical report template containing all the data required to enter the data of patients treated with CAR-T in the EBMT registry, in the CRF of the DESCAR-T registry and in the ATIH registry. This document aims to improve the completeness and quality of the data while optimizing data entry time.
Collapse
|
40
|
[Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S65-S71. [PMID: 33678408 DOI: 10.1016/j.bulcan.2020.11.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 11/10/2020] [Accepted: 11/14/2020] [Indexed: 11/21/2022]
Abstract
Chimeric antigen receptor (CAR) T cells are a new class of anti-cancer therapy that involves manipulating autologous or allogeneic T cells to express a CAR directed against a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) has marketing authorization for the treatment of relapsed / refractory acute lymphoblastic leukemia (ALL) in children and young adults, in addition to the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL); the marketing authorization for axicabtagene ciloleucel (Yescarta™) is for the treatment of relapsed / refractory high-grade B-cell lymphoma and for the treatment of primary mediastinal B-cell lymphoma. Both cell products are genetically modified autologous T cells directed against CD19. These recommendations, drawn up by a working group of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC) relate to the management of patients and the supply chain: medium-term complications, in particular cytopenias and B-cell aplasia, nursing and psychological supportive care. In another work, we will address long-term monitoring, post-marketing authorization pharmacovigilance and issues relating to JACIE and regulatory authorities. These recommendations are not prescriptive; their aim is to provide guidelines for the use of this new therapeutic approach. The purpose of this workshop is to outline the organizational aspects of this new therapeutic approach.
Collapse
|
41
|
Indications de l’autogreffe de cellules hématopoïétiques dans la Maladie de Crohn : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire. Bull Cancer 2020; 107:S140-S150. [DOI: 10.1016/j.bulcan.2020.08.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 08/25/2020] [Accepted: 08/29/2020] [Indexed: 01/25/2023]
|
42
|
Calmels B, Gautier É, Magnani A, Magrin É, Mamez AC, Vaissié A, Yakoub-Agha I, Baudoux É. Procédé de préparation, contrôles de qualité et spécifications des immunosélections CD34+ : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 2020; 107:S185-S192. [DOI: 10.1016/j.bulcan.2020.06.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 06/08/2020] [Accepted: 06/22/2020] [Indexed: 12/30/2022]
|
43
|
Beauvais D, Andrianne C, Aubrun C, Berquier M, Bole S, Caulier A, Courbon C, Delorme J, Fournier I, François G, Jaivenois MF, Le Bars L, Mussot I, Vercasson M, Wallart Brejaud A, Yakoub-Agha I, Lacroix D. Le parcours de soins du patient dans le cadre des CAR T-cell : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 2020; 107:S170-S177. [DOI: 10.1016/j.bulcan.2020.05.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2019] [Revised: 05/22/2020] [Accepted: 05/27/2020] [Indexed: 11/28/2022]
|
44
|
[Quality assessment of CAR T-cell activity: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2020; 107:S193-S201. [PMID: 33187683 DOI: 10.1016/j.bulcan.2020.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 10/22/2020] [Accepted: 10/27/2020] [Indexed: 11/23/2022]
Abstract
CAR T-cells are anti-cancer immunocellular therapy drugs that involve reprogramming the patient's T-cells using a transgene encoding a chimeric antigen receptor (CAR). Although CAR T-cells are cellular therapies, the organization for manufacturing and delivering these medicinal products is in many ways different from the one for hematopoietic cell grafts or donor lymphocyte infusions. The implementation of this innovative therapy is recent and requires close coordination between clinical teams, the therapeutic apheresis unit, the cell therapy unit, the pharmaceutical laboratory, and pharmacy. Apart from the regulatory texts, which are regularly modified, and the specific requirements of each pharmaceutical laboratory, there is currently no guide to help the centers initiating their activity and there is no specific indicator to assess the quality of the CAR T-cell activity in each center. The purpose of the current harmonization workshop is to clarify the regulatory prerequisites warranted for a center to have a CAR T-cell activity and to propose recommendations for implementing quality tools, in particular indicators, and allowing their sharing.
Collapse
|
45
|
Souchet L, Ahmad I, Hamzy F, Ceballos P, Desbrosses Y, Ravinet A, Turlure P, Villate A, Vigarios E, Borel C, Yakoub-Agha I, Guillaume T. [Oral complications following allogeneic hematopoietic cell transplantation: Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)]. Bull Cancer 2020; 107:S122-S129. [PMID: 32532421 DOI: 10.1016/j.bulcan.2020.03.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 03/16/2020] [Accepted: 03/17/2020] [Indexed: 10/24/2022]
Abstract
Stomatological complications of allogeneic hematopoietic stem cell transplantation (HSCT) are frequent and very uncomfortable for patients. The primary complication is the graft versus host disease reaction. Other side effects of the procedure include infections, taste disorders and carcinogenic risks. Various local treatments are used but remain imperfect. Within the framework of the 10th workshop of practice harmonization of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held in Lille in September 2019, diagnostic approaches and treatments of tongue and oral complications following allogeneic HSCT were reviewed according to the analysis of published studies.
Collapse
Affiliation(s)
- Laetitia Souchet
- Centre hospitalier La Pitié-Salpetrière, service d'hématologie, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - Imran Ahmad
- Hôpital Maisonneuve-Rosemont, service d'hématologie et oncologie médicale, 5415, boulevard de l'Assomption, H1T2M4 Montréal, QC, Canada
| | - Fati Hamzy
- Hôpital universitaire international Cheikh-Zaïd, service d'hématologie et greffe de moelle osseuse, Cite al Irfane-Hay Ryad avenue Allal-al-Fassi, 6533 Rabat BP, Maroc
| | - Patrice Ceballos
- Centre hospitalier Saint-Éloi, UGH hématologie, 80, avenue Augustin-Fliche, 34080 Montpellier, France
| | - Yohann Desbrosses
- CHRU Jean-Minjoz Besançon, service d'hématologie, 3, boulevard Flemming, 25030 Besançon cedex, France
| | - Aurélie Ravinet
- Université d'Auvergne, CHU d'Estaing, service d'hématologie, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France
| | - Pascal Turlure
- CHU de Dupuytren Limoges, service d'hématologie, 2, avenue Martin-Luther-King, 87000 Limoges, France
| | - Alban Villate
- CHU de Bretonneau Tours, service d'hématologie et thérapie cellulaire, 2, boulevard Tonnelé, 37044 Tours cedex 9, France
| | - Emmanuelle Vigarios
- Institut universitaire du cancer de Toulouse-Oncopole, service de chirurgie, 1, avenue Irène Joliot-Curie, 31100 Toulouse, France
| | - Cécile Borel
- Institut universitaire du cancer de Toulouse-Oncopole, service d'hématologie, 1, avenue Irène Joliot-Curie, 31100 Toulouse, France
| | - Ibrahim Yakoub-Agha
- Université de Lille, CHU de Lille, faculté de médecine, pôle recherche, INFINITE-U1286, Inserm, 4(e) étage Centre Place Verdun, 59045 Lille cedex, France
| | - Thierry Guillaume
- CHU de Nantes, hôtel Dieu, service d'hématologie clinique, 1, place Ricordeau, 44000 Nantes, France.
| |
Collapse
|
46
|
Brignier A, Ader V, Bellegarde K, Giraud C, Guerout-Verite MA, Hamzy F, Huynh TNP, Levavasseur A, Nacimento F, Rousseau Y, Vincent L, Yakoub-Agha I, De Vos J. Modalités de mobilisation des cellules souches hématopoïétiques autologues et objectifs cellulaires en cellules CD34 + : recommandations de la Société francophone de greffe de mœlle et de thérapie cellulaire (SFGM-TC). Bull Cancer 2020; 107:S44-S51. [DOI: 10.1016/j.bulcan.2019.08.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 08/22/2019] [Accepted: 08/29/2019] [Indexed: 01/08/2023]
|
47
|
Indications de l’autogreffe de cellules souches hématopoïétiques dans la polyradiculonévrite inflammatoire démyélinisante chronique : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 2020; 107:S104-S113. [DOI: 10.1016/j.bulcan.2019.11.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Revised: 11/11/2019] [Accepted: 11/16/2019] [Indexed: 12/29/2022]
|
48
|
Brissot E, Villate A, Alsuliman T, Beauvais D, Bonnin A, Mear JB, Souchet L, Yakoub-Agha I, Bazarbachi A. [Multidrug-resistant bacteria detection in patients undergoing allogeneic hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2019; 107:S7-S11. [PMID: 31635753 DOI: 10.1016/j.bulcan.2019.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2019] [Accepted: 09/23/2019] [Indexed: 11/25/2022]
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organizes annual workshops in the attempt to harmonize clinical practices among different francophone transplantation centers. Here we report our recommendations regarding detection of the multidrug-resistant bacteria in hematology.
Collapse
Affiliation(s)
- Eolia Brissot
- Sorbonne université, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, Inserm, UMRs 938, 75012 Paris, France.
| | - Alban Villate
- CHRU de Tours, service d'hématologie clinique, 37000 Tours, France
| | - Tamim Alsuliman
- Sorbonne université, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, Inserm, UMRs 938, 75012 Paris, France
| | - David Beauvais
- CHU de Lille, université de Lille, LIRIC, Inserm U995, 59000 Lille, France
| | - Agnès Bonnin
- Sorbonne université, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, Inserm, UMRs 938, 75012 Paris, France
| | | | - Laetitia Souchet
- Sorbonne université, hôpital La Pitié-Salpêtrière, service d'hématologie clinique, 75013 Paris, France
| | | | - Ali Bazarbachi
- American university of Beirut, department of internal medicine, Beyrouth, Liban
| |
Collapse
|
49
|
Dendoncker C, Brouillat C, Daufrene L, Deledicque V, El Cheikh J, Gibault-Joffe C, Guilbert Y, Guidi V, Hadrot L, Haran I, Kermeur G, Kernoa K, L'Hostette A, Mercier L, Mouneydier K, Servais S, Withofs S, Yakoub-Agha I, Farrugia C. [Oral feeding of patient hospitalized for allogeneic stem cells transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2019; 107:S36-S43. [PMID: 31615648 DOI: 10.1016/j.bulcan.2019.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 07/17/2019] [Accepted: 07/31/2019] [Indexed: 10/25/2022]
Abstract
Given the absence of consensus on oral feeding of patients undergoing allogeneic hematopoietic transplantation, the ninth workshops of practice harmonization of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) allocated one session to address this topic, especially during the hospitalization. A questionnaire was sent to all SFGM-TC pediatric and adult centers in order to investigate oral feeding practices. The results demonstrated a large disparity among centers regarding oral feeding. Here, we report our recommendations regarding the oral feeding after allogeneic hematopoietic cell transplantation in terms of quality, quantity and bacterial authorized load.
Collapse
Affiliation(s)
- Caroline Dendoncker
- CHR de Lille/Hôpital Claude-Huriez, service de nutrition, 2, avenue Oscar-Lambret, 59000 Lille, France.
| | - Carole Brouillat
- Institut de cancérologie de Lucien-Newirth, service de greffe, avenue Albert-Raimond, 42000 Saint-Priest-en-Jarez, France
| | - Leïla Daufrene
- CHU de Rouen, service de pédiatrie biberonnerie, 1, rue de Germont, 76000 Rouen, France
| | - Virginie Deledicque
- CHR de Lille/Hôpital Jeanne-de-Flandres, service de nutrition, 2, avenue Oscar-Lambret, 59000 Lille, France
| | - Jean El Cheikh
- American University of Beirut, Medical Center Beyrouth, service d'onco-hématologie, greffe de mœlle, Beirut, Liban
| | - Cécile Gibault-Joffe
- Hôpitaux universitaires de Genève, service d'hématologie, rue Gabrielle-Perret-Gentil 4, 1211 Genève, Suisse
| | - Yoann Guilbert
- Institut Paoli-Calmettes, service d'onco-hématologie, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cedex 9, France
| | - Virginie Guidi
- CHU de Clermont-Ferrand/Hôpital Estaing, service d'hématologie, 1, place Lucien-Aubrac, 63000 Clermont-Ferrand cedex 1, France
| | - Lisa Hadrot
- CHU de Strasbourg/Hôpital de Hautepierre, service d'onco-hématologie, 1, avenue Molière, 67098 Strasbourg cedex, France
| | - Isabelle Haran
- CHU de Strasbourg/Hôpital de Hautepierre, service d'onco-hématologie pédiatrique, 1, avenue Molière, 67098 Strasbourg cedex, France
| | - Guénola Kermeur
- CHU de Rennes, service d'hématologie adulte, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France
| | - Kim Kernoa
- CHU d'Amiens-Picardie, service d'onco-hématologie, place Victor-Pauchet, 80054 Amiens, France
| | - Alexandra L'Hostette
- CHU de Montpellier/CHU d'Arnaud de Villeneuve, service d'onco-hématologie pédiatrique, 295, avenue Gaston-Guiraud, 34595 Montpellier cedex 5, France
| | - Lara Mercier
- CHU de Toulouse, institut universitaire du cancer de Toulouse oncopole, service d'hématologie hautement protégée/greffe, 1, avenue Irène-Joliot-Curie, 31095 Toulouse, France
| | - Karine Mouneydier
- CHU de Bordeaux, hôpital des Enfants, service d'hématologie pédiatrique, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - Sophie Servais
- CHU de Liège, service d'hématologie, 1, avenue de l'Hôpital, 4000 Liege, Belgique
| | - Sabine Withofs
- CHU de Liège, service d'hématologie, 1, avenue de l'Hôpital, 4000 Liege, Belgique
| | | | - Carole Farrugia
- CHU de Montpellier, CHU de Saint-Éloi, service d'hématologie-onco médicale, 80, avenue Augustin-Fliche, 34000 Montpellier, France
| |
Collapse
|
50
|
Brissot E, Alsuliman T, Beauvais D, Bonnin A, Mear JB, Souchet L, Villate A, Yakoub-Agha I, Bazarbachi A. [Antiviral prophylaxis for CMV, HSV/VZV and HBV in allogeneic hematopoietic cell transplantation in adult patients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2019; 107:S1-S6. [PMID: 31627903 DOI: 10.1016/j.bulcan.2019.09.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2019] [Revised: 07/14/2019] [Accepted: 09/04/2019] [Indexed: 02/08/2023]
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organizes annual workshops in the attempt to harmonize clinical practices among different francophone transplantation centers. Here, we report our recommendations regarding the prophylaxis of cytomegalovirus (CMV), herpes simplex virus (HSV), varicella zoster virus (VZV) and hepatitis B virus infection after allogeneic hematopoietic cell transplantation in adult patients.
Collapse
Affiliation(s)
- Eolia Brissot
- Hôpital Saint-Antoine, Sorbonne université, service d'hématologie clinique et thérapie cellulaire, Inserm, UMRs 938, 75012 Paris, France.
| | - Tamim Alsuliman
- Hôpital Saint-Antoine, Sorbonne université, service d'hématologie clinique et thérapie cellulaire, Inserm, UMRs 938, 75012 Paris, France
| | - David Beauvais
- Université de Lille, CHU de Lille, LIRIC, Inserm U995, 59000 Lille, France
| | - Agnès Bonnin
- Hôpital Saint-Antoine, Sorbonne université, service d'hématologie clinique et thérapie cellulaire, Inserm, UMRs 938, 75012 Paris, France
| | | | - Laetitia Souchet
- Hôpital La Pitié-Salpétrière, Sorbonne université, service d'hématologie clinique, 75013 Paris, France
| | - Alban Villate
- CHRU de Tours, service d'hématologie clinique, 37000 Tours, France
| | | | - Ali Bazarbachi
- American university of Beirut, department of internal medicine, Beyrouth, Liban
| |
Collapse
|